<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation - Estcourt, LJ - 2015 | Cochrane Library</title> <meta content="Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation - Estcourt, LJ - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010983.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation - Estcourt, LJ - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010983.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010983.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation" name="citation_title"/> <meta content="Lise J Estcourt" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="lise.estcourt@nhsbt.nhs.uk" name="citation_author_email"/> <meta content="Simon J Stanworth" name="citation_author"/> <meta content="Oxford University Hospitals NHS Foundation Trust and the University of Oxford" name="citation_author_institution"/> <meta content="Carolyn Doree" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Sally Hopewell" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Marialena Trivella" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Michael F Murphy" name="citation_author"/> <meta content="Oxford University Hospitals and the University of Oxford" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD010983.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/11/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010983.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010983.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010983.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antineoplastic Agents [adverse effects]; Bone Marrow Diseases [chemically induced]; Hematologic Diseases [chemically induced, *complications]; Hemorrhage [*prevention &amp; control]; Platelet Count [*standards]; *Platelet Transfusion; Randomized Controlled Trials as Topic; Stem Cell Transplantation [*adverse effects]; Thrombocytopenia [etiology, *therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010983.pub2&amp;doi=10.1002/14651858.CD010983.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="PrHmaMrX";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010983\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010983\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010983.pub2",title:"Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation",firstPublishedDate:"Nov 18, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematological Malignancies Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010983.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010983.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010983.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010983.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010983.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010983.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010983.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010983.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010983.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010983.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2453 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010983.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-sec-0119"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-sec-0024"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-sec-0025"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-sec-0059"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-sec-0113"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/appendices#CD010983-sec-0125"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/table_n/CD010983StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/table_n/CD010983StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/information#CD010983-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Lise J Estcourt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/information#CD010983-cr-0003">Simon J Stanworth</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/information#CD010983-cr-0004">Carolyn Doree</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/information#CD010983-cr-0005">Sally Hopewell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/information#CD010983-cr-0006">Marialena Trivella</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010983.pub2/information#CD010983-cr-0007">Michael F Murphy</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/information/en#CD010983-sec-0142">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 November 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010983.pub2">https://doi.org/10.1002/14651858.CD010983.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010983-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010983-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010983-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010983-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010983-abs-0001" lang="en"> <section id="CD010983-sec-0001"> <h3 class="title" id="CD010983-sec-0001">Background</h3> <p>Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in people who are thrombocytopenic due to bone marrow failure. Although considerable advances have been made in platelet transfusion therapy in the last 40 years, some areas continue to provoke debate, especially concerning the use of prophylactic platelet transfusions for the prevention of thrombocytopenic bleeding. </p> <p>This is an update of a Cochrane review first published in 2004, and previously updated in 2012 that addressed four separate questions: prophylactic versus therapeutic‐only platelet transfusion policy; prophylactic platelet transfusion threshold; prophylactic platelet transfusion dose; and platelet transfusions compared to alternative treatments. This review has now been split into four smaller reviews looking at these questions individually; this review compares prophylactic platelet transfusion thresholds. </p> </section> <section id="CD010983-sec-0002"> <h3 class="title" id="CD010983-sec-0002">Objectives</h3> <p>To determine whether different platelet transfusion thresholds for administration of prophylactic platelet transfusions (platelet transfusions given to prevent bleeding) affect the efficacy and safety of prophylactic platelet transfusions in preventing bleeding in people with haematological disorders undergoing myelosuppressive chemotherapy or haematopoietic stem cell transplantation (HSCT). </p> </section> <section id="CD010983-sec-0003"> <h3 class="title" id="CD010983-sec-0003">Search methods</h3> <p>We searched for randomised controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library 2015, Issue 6, 23 July 2015), MEDLINE (from 1946), Embase (from 1974), CINAHL (from 1937), the Transfusion Evidence Library (from 1950), and ongoing trial databases to 23 July 2015. </p> </section> <section id="CD010983-sec-0004"> <h3 class="title" id="CD010983-sec-0004">Selection criteria</h3> <p>We included RCTs involving transfusions of platelet concentrates, prepared either from individual units of whole blood or by apheresis, and given to prevent bleeding in people with haematological disorders (receiving myelosuppressive chemotherapy or undergoing HSCT) that compared different thresholds for administration of prophylactic platelet transfusions (low trigger (5 x 10<sup>9</sup>/L); standard trigger (10 x 10<sup>9</sup>/L); higher trigger (20 x 10<sup>9</sup>/L, 30 x 10<sup>9</sup>/L, 50 x 10<sup>9</sup>/L); or alternative platelet trigger (for example platelet mass)). </p> </section> <section id="CD010983-sec-0005"> <h3 class="title" id="CD010983-sec-0005">Data collection and analysis</h3> <p>We used the standard methodological procedures expected by Cochrane.</p> </section> <section id="CD010983-sec-0006"> <h3 class="title" id="CD010983-sec-0006">Main results</h3> <p>Three trials met our predefined inclusion criteria and were included for analysis in the review (499 participants). All three trials compared a standard trigger (10 x 10<sup>9</sup>/L) versus a higher trigger (20 x 10<sup>9</sup>/L or 30 x 10<sup>9</sup>/L). None of the trials compared a low trigger versus a standard trigger or an alternative platelet trigger. The trials were conducted between 1991 and 2001 and enrolled participants from fairly comparable patient populations. </p> <p>The original review contained four trials (658 participants); in the previous update of this review we excluded one trial (159 participants) because fewer than 80% of participants had a haematological disorder. We identified no new trials in this update of the review. </p> <p>Overall, the methodological quality of the studies was low across different outcomes according to GRADE methodology. None of the included studies were at low risk of bias in every domain, and all the included studies had some threats to validity. </p> <p>Three studies reported the number of participants with at least one clinically significant bleeding episode within 30 days from the start of the study. There was no evidence of a difference in the number of participants with a clinically significant bleeding episode between the standard and higher trigger groups (three studies; 499 participants; risk ratio (RR) 1.35, 95% confidence interval (CI) 0.95 to 1.90; low‐quality evidence). </p> <p>One study reported the number of days with a clinically significant bleeding event (adjusted for repeated measures). There was no evidence of a difference in the number of days of bleeding per participant between the standard and higher trigger groups (one study; 255 participants; relative proportion of days with World Health Organization Grade 2 or worse bleeding (RR 1.71, 95% CI 0.84 to 3.48, P = 0.162; authors' own results; low‐quality evidence). </p> <p>Two studies reported the number of participants with severe or life‐threatening bleeding. There was no evidence of any difference in the number of participants with severe or life‐threatening bleeding between a standard trigger level and a higher trigger level (two studies; 421 participants; RR 0.99, 95% CI 0.52 to 1.88; low‐quality evidence). </p> <p>Only one study reported the time to first bleeding episode. There was no evidence of any difference in the time to the first bleeding episode between a standard trigger level and a higher trigger level (one study; 255 participants; hazard ratio 1.11, 95% CI 0.64 to 1.91; low‐quality evidence). </p> <p>Only one study reported on all‐cause mortality within 30 days from the start of the study. There was no evidence of any difference in all‐cause mortality between standard and higher trigger groups (one study; 255 participants; RR 1.78, 95% CI 0.83 to 3.81; low‐quality evidence). </p> <p>Three studies reported on the number of platelet transfusions per participant. Two studies reported on the mean number of platelet transfusions per participant. There was a significant reduction in the number of platelet transfusions per participant in the standard trigger group (two studies, mean difference ‐2.09, 95% CI ‐3.20 to ‐0.99; low‐quality evidence). </p> <p>One study reported on the number of transfusion reactions. There was no evidence to demonstrate any difference in transfusion reactions between the standard and higher trigger groups (one study; 79 participants; RR 0.07, 95% CI 0.00 to 1.09). </p> <p>None of the studies reported on quality of life.</p> </section> <section id="CD010983-sec-0007"> <h3 class="title" id="CD010983-sec-0007">Authors' conclusions</h3> <p>In people with haematological disorders who are thrombocytopenic due to myelosuppressive chemotherapy or HSCT, we found low‐quality evidence that a standard trigger level (10 x 10<sup>9</sup>/L) is associated with no increase in the risk of bleeding when compared to a higher trigger level (20 x 10<sup>9</sup>/L or 30 x 10<sup>9</sup>/L). There was low‐quality evidence that a standard trigger level is associated with a decreased number of transfusion episodes when compared to a higher trigger level (20 x 10<sup>9</sup>/L or 30 x 10<sup>9</sup>/L). </p> <p>Findings from this review were based on three studies and 499 participants. Without further evidence, it is reasonable to continue with the current practice of administering prophylactic platelet transfusions using the standard trigger level (10 x 10<sup>9</sup>/L) in the absence of other risk factors for bleeding. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010983-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010983-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010983-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010983-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010983-abs-0004">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010983-abs-0003" lang="en"> <h3>Platelet transfusions are used to prevent bleeding in people with low platelet counts due to treatment‐induced bone marrow failure </h3> <p><b>Review question</b> </p> <p>We evaluated the evidence about whether platelet transfusions given to prevent bleeding in people with lower platelet counts (for example 5 x 10<sup>9</sup>/L or below) were as effective and safe as the current standard (10 x 10<sup>9</sup>/L or below), or whether higher platelet count levels (20 x 10<sup>9</sup>/L or below, 30 x 10<sup>9</sup>/L or below, or 50 x 10<sup>9</sup>/L or below) were safer than the current standard (10 x 10<sup>9</sup>/L or below). Our target population was people with blood cancers (for example leukaemia, lymphoma, myeloma) who were receiving intensive (myelosuppressive) chemotherapy treatments or stem cell transplantation. </p> <p><b>Background</b> </p> <p>People with blood cancers may have low platelet counts due to their underlying cancer. Blood cancers may be treated with chemotherapy and stem cell transplantation, and these treatments can cause low platelet counts. Platelet transfusions may be given to prevent bleeding when the platelet count falls below a prespecified threshold platelet count (for example 10 x 10<sup>9</sup>/L), or may be given to treat bleeding (such as a prolonged nosebleed or multiple bruises). Giving platelet transfusions at a lower prespecified threshold platelet count may increase the chance that bleeding will occur, which may be harmful, whereas giving platelet transfusions at a higher prespecified threshold platelet count may mean that people receive unnecessary platelet transfusions. Platelet transfusions can have adverse effects and have cost and resource implications for health services, so unnecessary transfusions should be avoided. </p> <p><b>Study characteristics</b> </p> <p>The evidence is current to July 2015. We found no new studies in this update of the review. This review identified three randomised controlled trials that compared giving platelet transfusions to prevent bleeding when the platelet count is 10 x 10<sup>9</sup>/L (the current standard) or below versus giving platelet transfusions to prevent bleeding at higher platelet count levels (20 x 10<sup>9</sup>/L or below or 30 x 10<sup>9</sup>/L or below). None of the studies compared a lower trigger or alternative trigger to the current standard. These trials were conducted between 1991 and 2001 and included 499 participants. Two trials included adults with leukaemia who were receiving chemotherapy. One trial included children and adults receiving a stem cell transplant. </p> <p>Two of the three studies reported sources of funding. Neither of the studies that reported funding sources were industry sponsored. </p> <p><b>Key results</b> </p> <p>Giving platelet transfusions to people with low platelet counts due to blood cancers or their treatment to prevent bleeding when the platelet count was 10 x 10<sup>9</sup>/L or below did not increase the risk of bleeding compared to giving a platelet transfusion at higher platelet counts (20 x 10<sup>9</sup>/L or below or 30 x 10<sup>9</sup>/L or below). </p> <p>Giving platelet transfusions to prevent bleeding only when the platelet count was 10 x 10<sup>9</sup>/L or below resulted in a reduction in the number of platelets given. We found no evidence to demonstrate that giving a platelet transfusion when the platelet count was 10 x 10<sup>9</sup>/L or below decreased the number of transfusion reactions compared to giving platelet transfusions at higher platelet counts (20 x 10<sup>9</sup>/L or below or 30 x 10<sup>9</sup>/L or below). </p> <p>None of the three studies reported any quality of life outcomes.</p> <p>Findings from this review were based on three studies and 499 participants. Without further evidence, it is reasonable to continue using platelet transfusions to prevent bleeding based on the current standard transfusion threshold (10 x 10<sup>9</sup>/L). </p> <p><b>Quality of the evidence</b> </p> <p>The evidence for most of the findings was of low quality. This was because participants and their doctors knew which study arm the participant had been allocated to, and also the estimate of the treatment effect was imprecise. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010983-sec-0119" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010983-sec-0119"></div> <h3 class="title" id="CD010983-sec-0120">Implications for practice</h3> <section id="CD010983-sec-0120"> <p>The evidence from this review does not clearly show equivalence of a threshold of 10 x 10<sup>9</sup>/L and 20 x 10<sup>9</sup>/L or 30 x 10<sup>9</sup>/L due to the imprecision of the estimates for the outcomes measured within this review (number of participants with at least one clinically significant bleeding event up to 30 days from study entry; number of participants with WHO Grade 3 or 4 bleeding up to 30 days from study entry; time to first clinically significant bleeding event; mortality from all causes up to 30 days from study entry; number of platelet transfusions per participant). However, without further evidence it is reasonable to continue with the current practice of a platelet transfusion threshold of 10 x 10<sup>9</sup>/L in the absence of other risk factors for bleeding. This practice reduces platelet utilisation and donor exposure. </p> <p>The effectiveness and safety of the three other planned comparisons cannot be commented on because no study assessed these comparisons. These planned comparisons were: a lower platelet count threshold (5 x 10<sup>9</sup>/L) versus standard platelet transfusion threshold (10 x 10<sup>9</sup>/L); different platelet count thresholds (5 x 10<sup>9</sup>/L, 20 x 10<sup>9</sup>/L, 30 x 10<sup>9</sup>/L, or 50 x 10<sup>9</sup>/L) that did not include a comparison against the standard platelet transfusion threshold (10 x 10<sup>9</sup>/L); alternative thresholds to guide prophylactic platelet transfusions (for example platelet mass, immature platelet fraction, absolute immature platelet number). </p> </section> <h3 class="title" id="CD010983-sec-0121">Implications for research</h3> <section id="CD010983-sec-0121"> <p>Conclusions on the non‐inferiority of a platelet count threshold of 10 x 10<sup>9</sup>/L compared to 20 x 10<sup>9</sup>/L or 30 x 10<sup>9</sup>/L have been based on underpowered studies leading to imprecise estimates for the outcomes within this review. In the <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a> study (255 participants), the power calculations were based on the assumption that the rate of WHO Grade 2 or above bleeding was 30%, but the actual rate in this study was 20%. To detect a 50% increase in the rate of bleeding (that is from 20% to 30%) with 90% power would require 392 participants per arm of the study, and to detect a 25% increase in the rate of bleeding (that is from 20% to 25%) with 80% power would require 1098 participants per arm of the study. The combined results from all three studies would not be sufficiently powered to detect a 50% increase in the rate of bleeding in the standard platelet transfusion threshold (10 x 10<sup>9</sup>/L) arm, if we assumed the rate of bleeding was 20% in all three studies. </p> <p>No RCTs have compared a lower platelet count threshold (5 x 10<sup>9</sup>/L) versus standard platelet transfusion threshold (10 x 10<sup>9</sup>/L); different platelet count thresholds (5 x 10<sup>9</sup>/L, 20 x 10<sup>9</sup>/L, 30 x 10<sup>9</sup>/L, or 50 x 10<sup>9</sup>/L) that did not include a comparison against the standard platelet transfusion threshold (10 x 10<sup>9</sup>/L); or alternative thresholds to guide prophylactic platelet transfusions (for example platelet mass, immature platelet fraction, absolute immature platelet number) in people with haematological malignancies. </p> <p>Additional evidence is required from new RCTs to determine the most appropriate platelet transfusion threshold to guide prophylactic platelet transfusions. </p> <section id="CD010983-sec-0122"> <h5 class="title">Assessment of bleeding in future trials</h5> <p>One of the difficulties within this review was the variability between studies in assessing and grading bleeding. The WHO classification of bleeding, although widely used, has never been validated, and therefore the assumption that all Grade 2 bleeding is clinically significant has been brought into question. For future studies, an international consensus on assessing and grading bleeding would greatly enhance the ability to compare platelet transfusion trials. This would need to be validated and to take into account the impact that bleeding has upon the patient from both a medical perspective and with regard to quality of life. </p> <p>It is acknowledged that blinding in platelet transfusion trials is difficult. However, whenever possible, the bleeding assessor should be blinded to the intervention. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010983-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010983-sec-0015"></div> <div class="table" id="CD010983-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Prophylactic platelet transfusion at threshold of 10,000 compared to higher transfusion threshold (20,000 or 30,000) for people with a haematological disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylactic platelet transfusion at threshold of 10,000 compared to higher transfusion threshold (20,000 or 30,000) for prevention of haemorrhage after chemotherapy and stem cell transplantation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with a haematological disorder<br/> <b>Settings:</b> Receiving intensive chemotherapy or a stem cell transplant<br/> <b>Intervention:</b> Prophylactic platelet transfusion at threshold of 10 x 10<sup>9</sup>/L<br/> <b>Comparison:</b> Higher transfusion threshold (20 x 10<sup>9</sup>/L or 30 x 10<sup>9</sup>/L) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Higher transfusion threshold </b> </p> <p><b> (20 x 10<sup>9</sup>/L or 30 x 10<sup>9</sup>/L)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Prophylactic platelet transfusion at threshold of 10 x 10<sup>9</sup>/L</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Numbers of participants with at least 1 clinically significant bleeding event up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> <br/> (168 to 336) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.35</b> <br/> (0.95 to 1.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The definition of clinically significant bleeding varied between studies, because there were differences in the way bleeding was graded </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of days on which clinically significant bleeding occurred per participant up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>3</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with WHO Grade 3 or 4 bleeding up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>82 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b> </p> <p>(43 to 154)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> </p> <p>(0.52 to 1.88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>421</p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first bleeding episode (days)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.11</b> </p> <p>(0.64 to 1.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of platelet transfusions per participant up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean number of platelet transfusions per participant in the 10 x 10<sup>9</sup>/L group was<br/> <b>2.09 lower</b> <br/> (3.2 to 0.99 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality from all causes up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>134 per 1000</b> </p> <p>(62 to 286)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.78</b> </p> <p>(0.83 to 3.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies reported quality of life</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>HR:</b> Hazard ratio; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The number of participants from all three studies may not be large enough to detect a clinically significant difference. The confidence intervals are wide, and therefore there is uncertainty about the result. The level of evidence was downgraded by 1 due to imprecision. </p> <p><sup>2</sup>All of the studies were at high risk of bias due to lack of blinding and more protocol deviations in the standard‐trigger arm (10 x 10<sup>9</sup>/L). The Rebulla study did not perform an intention‐to‐treat analysis and excluded 2 participants who died within 24 hours of entering the study. The level of evidence was downgraded by 1 due to risk of bias. </p> <p><sup>3</sup>The authors of <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a> reported a relative proportion of days with WHO Grade 2 or worse bleeding of 1.71 (95% CI 0.84 to 3.48) for the standard versus higher transfusion trigger arms. A permutation test for the comparison of these proportions gives a P value of 0.162, and therefore no significant difference between study arms was found. These results are the authors' own results. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010983-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010983-sec-0016"></div> <section id="CD010983-sec-0017"> <h3 class="title" id="CD010983-sec-0017">Description of the condition</h3> <p>Haematological malignancies account for between 8% and 9% of all new cancers reported in the United Kingdom and United States (<a href="./references#CD010983-bbs2-0175" title="CDC (Centers for Disease Control and Prevention). United States Cancer Statistics. National Program of Cancer Registries (NPCR) http://www.cdc.gov/cancer/npcr/ 2012 (accessed 14 February 2013). ">CDC 2012</a>; <a href="./references#CD010983-bbs2-0205" title="Office for National Statistics. Cancer incidence and mortality tables and charts. http://www.ons.gov.uk/ons/index.html 2012 (accessed 14 February 2013), issue tcm77‐259491. ">ONS 2012</a>), and their incidence is increasing (11% to 14% increase in new cases of lymphoma and myeloma between 1991 to 2001 and 2008 to 2010, respectively) (<a href="./references#CD010983-bbs2-0174" title="Cancer Research UK. Percentage change in European age‐standardised three year average incidence rates, males, UK, 1991‐2001 and 2008‐2010. Cancer Research UK statistics at http://www.cancerresearchuk.org/cancer‐info/cancerstats/ (accessed 14 February 2013). ">Cancer Research UK 2013</a>). The prevalence of these disorders is also increasing due to increased survival rates (<a href="./references#CD010983-bbs2-0176" title="ColemanMP , RachetB , WoodsLM , MitryE , RigaM , CooperN , et al. Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. British Journal of Cancer2004;90(7):1367‐73. ">Coleman 2004</a>; <a href="./references#CD010983-bbs2-0213" title="RachetB , MaringeC , NurU , QuaresmaM , ShahA , WoodsLM , et al. Population‐based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. The Lancet Oncology 10;4:351‐69. ">Rachet 2009</a>), which are the result of the introduction of intensive chemotherapy treatments and use of stem cell transplantation (<a href="./references#CD010983-bbs2-0172" title="BurnettAK , HillsRK , MilliganD , KjeldsenL , KellJ , RussellNH , et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. Journal of Clinical Oncology2011;29(4):369‐77. ">Burnett 2011</a>; <a href="./references#CD010983-bbs2-0188" title="FieldingAK , RichardsSM , ChopraR , LazarusHM , LitzowMR , BuckG , et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood2007;109(3):944‐50. [PUBMED: 17032921] ">Fielding 2007</a>; <a href="./references#CD010983-bbs2-0208" title="PatelB , KirklandK , SzydloR , PearceR , ClarkR , CraddockC , et al. Favorable outcomes with alemtuzumab‐conditioned unrelated donor stem cell transplantation in adults with high‐risk Philadelphia chromosome‐negative acute lymphoblastic leukemia in first complete remission. Haematologica2009;94:1399‐406. ">Patel 2009</a>). Over 50,000 haematopoietic stem cell transplants (HSCT) are carried out annually worldwide and are used to treat both malignant and non‐malignant haematological disorders (<a href="./references#CD010983-bbs2-0192" title="GratwohlA , BaldomeroH , AljurfM , PasquiniMC , BouzasLF , YoshimiA , et al. Hematopoietic stem cell transplantation: a global perspective. JAMA2010;303(16):1617‐24. ">Gratwohl 2010</a>). Autologous HSCT is the most common type of HSCT (57% to 59%) (<a href="./references#CD010983-bbs2-0192" title="GratwohlA , BaldomeroH , AljurfM , PasquiniMC , BouzasLF , YoshimiA , et al. Hematopoietic stem cell transplantation: a global perspective. JAMA2010;303(16):1617‐24. ">Gratwohl 2010</a>; <a href="./references#CD010983-bbs2-0207" title="PasswegJR , BaldomeroH , GratwohlA , BregniM , CesaroS , DregerP , et al. The EBMT activity survey: 1990‐2010. Bone Marrow Transplant2012;47(7):906‐23. ">Passweg 2012</a>). However, chemotherapy or stem cell transplantation can lead to prolonged periods of severe thrombocytopenia (<a href="./references#CD010983-bbs2-0178" title="De laSernaJ , MontesinosP , VellengaE , RayonC , ParodyR , LeonA , et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all‐trans retinoic acid and idarubicin. Blood2008;111(7):3395‐402. ">De la Serna 2008</a>; <a href="./references#CD010983-bbs2-0195" title="HeddleNM , CookRJ , TinmouthA , KouroukisCT , HervigT , KlapperE , et al. A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood2009;113(7):1564‐73. ">Heddle 2009a</a>; <a href="./references#CD010983-bbs2-0215" title="RyslerC , StoffelN , BuserA , GratwohlA , TsakirisDA , SternM . Effect of beta‐blockers, Ca2+antagonists, and benzodiazepines on bleeding incidence in patients with chemotherapy induced thrombocytopenia. Platelets2010;21(1):77‐83. ">Rysler 2010</a>; <a href="./references#CD010983-bbs2-0135" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al. TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394‐403. ISRCTN08758735 . A randomised controlled trial of prophylactic versus no‐prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled‐trials.com/ISRCTN08758735 (accessed 6 February 2010). PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions ‐ how was consistency achieved [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. Transfusion Medicine2013;23:46‐7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163‐71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no‐prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non‐inferiority trial. Blood2012;120(Supplement 1):Abstract 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385‐93. StanworthSJ , EstcourtLJ , PowterG , KahanB , DyerC , ChooL , et al. A no‐prophylaxis platelet transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771‐80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740‐7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):Abstract. ">Stanworth 2013</a>; <a href="./references#CD010983-bbs2-0154" title="NCT00521664 . A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664 (accessed 4 January 2010). Schaefer‐EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):Abstract. Schaefer‐EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):Abstract. WandtH , Schaefer‐EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):Abstract. WandtH , Schaefer‐EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):Abstract. WandtH , Schaefer‐EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open‐label, multicentre, randomised study. The Lancet2012;380(9850):1309‐16. WandtH , Schäfer‐EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high‐dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , WendelinK , Schaefer‐EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> <p>Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in thrombocytopenic patients with bone marrow failure secondary to chemotherapy or stem cell transplantation. The ready availability of platelet concentrates has undoubtedly made a major contribution in allowing the development of intensive treatment regimens for haematological disorders (malignant and non‐malignant) and other malignancies. The first demonstration of the effectiveness of platelet transfusions was performed in 1910 (<a href="./references#CD010983-bbs2-0180" title="DukeWW . The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and coagulation time and report of 3 cases of hemorrhagic disease relieved by transfusion. Journal of the American Medical Association1910;55:1185‐92. ">Duke 1910</a>). However, it was not until the 1970s and 1980s that the use of platelet transfusions became standard treatment for thrombocytopenic patients with bone marrow failure (<a href="./references#CD010983-bbs2-0016" title="BlajchmanMA , SlichterSJ , HeddleNM , MurphyMF . New strategies for the optimal use of platelet transfusions. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program2008;2008:198‐204. ">Blajchman 2008</a>). Alongside changes in supportive care, the routine use of platelet transfusions in people with haematological disorders since that time has led to a marked decrease in the number of haemorrhagic deaths associated with thrombocytopenia (<a href="./references#CD010983-bbs2-0222" title="SlichterSJ . Controversies in platelet transfusion therapy. Annual Reviews of Medicine1980;31:509‐40. ">Slichter 1980</a>). This has resulted in a considerable increase in the demand for platelet concentrates. Currently, platelet concentrates are the second most frequently used blood component. Administration of platelet transfusions to people with haematological disorders now constitutes a significant proportion (up to 67%) of all platelets issued (<a href="./references#CD010983-bbs2-0022" title="CameronB , RockG , OlbergB , NeurathD . Evaluation of platelet transfusion triggers in a tertiary‐care hospital. Transfusion2007;47(2):206‐11. ">Cameron 2007</a>; <a href="./references#CD010983-bbs2-0051" title="GreenoE , McCulloughJ , WeisdorfD . Platelet utilisation and the transfusion trigger: A prospective analysis. Transfusion2007;72(2):201‐5. ">Greeno 2007</a>; <a href="./references#CD010983-bbs2-0211" title="PendryK , DaviesT . An audit of use and wastage in the north west of England and North Wales: where have all the platelets gone?. Blood and Transplant Matters2011;34:17‐9. ">Pendry 2011</a>), and the majority of these (69%) are given to prevent bleeding (<a href="./references#CD010983-bbs2-0182" title="EstcourtLJ , BirchallJ , LoweD , Grant‐CaseyJ , RowleyM , MurphyMF . Platelet transfusions in haematology patients: are we using them appropriately?. Vox Sanguinis2012;103(4):284‐93. ">Estcourt 2012b</a>). </p> <p>People can become refractory to platelet transfusions. In an analysis of the <a href="./references#CD010983-bbs2-0144" title="EnrightH , DavisK , GernsheimerT , McCulloughJJ , WoodsonR , SlichterSJ . Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion2003;43(11):1545‐52. SlichterSJ , DavisK , EnrightH , BraineH , GernsheimerT , KaoKJ , et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood2005;105(10):4106‐14. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The New England Journal of Medicine1997;337:1861‐70. ">TRAP 1997</a> study data, there was a progressive decrease in the post‐transfusion platelet count increments and time interval between transfusions as the number of preceding transfusions increased (<a href="./references#CD010983-bbs2-0223" title="SlichterSJ , DavisK , EnrightH , BraineH , GernsheimerT , KaoKJ , et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood2005;105:4106‐14. ">Slichter 2005</a>). This effect was seen irrespective of whether or not participants had developed detectable human leukocyte antigen (HLA) antibodies (<a href="./references#CD010983-bbs2-0223" title="SlichterSJ , DavisK , EnrightH , BraineH , GernsheimerT , KaoKJ , et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood2005;105:4106‐14. ">Slichter 2005</a>). </p> <p>Platelet transfusions are also associated with adverse events. Mild to moderate reactions to platelet transfusions include rigors, fever, and urticaria (<a href="./references#CD010983-bbs2-0196" title="HeddleNM , WebbertK . Investigation of acute transfusion reactions. In: MurphyMF , PamphilionDH editor(s). Practical Transfusion Medicine. 4th Edition. Blackwell, 2009:63‐89. ">Heddle 2009b</a>). Although these reactions are not life‐threatening, they can be extremely distressing for the patient. Rarer but more serious sequelae include anaphylaxis, transfusion‐transmitted infections, transfusion‐related acute lung injury, and immunomodulatory effects (<a href="./references#CD010983-bbs2-0167" title="BensonAB , MossM , SillimanCC . Transfusion‐related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. British Journal of Haematology2009;147(4):431‐43. ">Benson 2009</a>; <a href="./references#CD010983-bbs2-0169" title="BlumbergN , SpinelliSL , FrancisCW , TaubmanMB , PhippsRP . The platelet as an immune cell ‐ CD40 ligand and transfusion immune modulation. Immunology Research2009;45:251‐60. ">Blumberg 2009</a>; <a href="./references#CD010983-bbs2-0171" title="Bolton‐Maggs PHB (Ed) and H Cohen on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2011 Annual SHOT Report. Serious Hazards of Transfusion (SHOT), 2012. ">Bolton‐Maggs 2012</a>; <a href="./references#CD010983-bbs2-0196" title="HeddleNM , WebbertK . Investigation of acute transfusion reactions. In: MurphyMF , PamphilionDH editor(s). Practical Transfusion Medicine. 4th Edition. Blackwell, 2009:63‐89. ">Heddle 2009b</a>; <a href="./references#CD010983-bbs2-0200" title="KnowlesS (Ed) , CohenH , on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2010 Annual SHOT Report. Serious Hazards of Transfusion (SHOT), 2011. ">Knowles 2011</a>; <a href="./references#CD010983-bbs2-0210" title="PearceS , RoweGP , FieldSP . Screening of platelet for bacterial contamination at the Welsh Blood Service. Transfusion Medicine2011;21(1):25‐32. ">Pearce 2011</a>; <a href="./references#CD010983-bbs2-0212" title="PopovskyMA , MooreSB . Diagnostic and pathogenetic considerations in transfusion‐related acute lung injury. Transfusion1985;25:573‐7. ">Popovsky 1985</a>; <a href="./references#CD010983-bbs2-0220" title="SillimanCC , BoshkovLK , MehdizadehkashiZ , ElziDJ , DickeyWO , PodloskyL , et al. Transfusion‐related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood2003;101(2):454‐62. ">Silliman 2003</a>; <a href="./references#CD010983-bbs2-0227" title="TaylorC (Ed) , CohenH , MoldD , JonesH , et al. on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2009 Annual SHOT Report. SHOT Steering Group, 2010. ">Taylor 2010</a>). </p> <p>Any strategy that can safely decrease the need for prophylactic platelet transfusions in people with haematological malignancies will have significant logistical and financial implications as well as decreasing patients’ exposure to the risks of transfusion. </p> </section> <section id="CD010983-sec-0018"> <h3 class="title" id="CD010983-sec-0018">Description of the intervention</h3> <p>Platelet transfusions have an obvious beneficial effect in the management of active bleeding in people with haematological malignancy and severe thrombocytopenia. However, questions still remain about how this limited resource should be used to prevent severe and life‐threatening bleeding (<a href="./references#CD010983-bbs2-0181" title="EstcourtLJ , StanworthSJ , MurphyMF . Platelet transfusions for patients with haematological malignancies: who needs them?. British Journal of Haematology2011;154(4):425‐40. ">Estcourt 2011</a>). Prophylactic platelet transfusions for people with chemotherapy‐induced thrombocytopenia became standard practice following the publication of several small randomised controlled trials (RCTs) in the late 1970s and early 1980s (<a href="./references#CD010983-bbs2-0065" title="HigbyDJ , CohenE , HollandJF , SinksL . The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion1974;14:440‐5. ">Higby 1974</a>; <a href="./references#CD010983-bbs2-0091" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347‐56. ">Murphy 1982</a>; <a href="./references#CD010983-bbs2-0132" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non‐lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>). </p> <section id="CD010983-sec-0019"> <h4 class="title">Prophylactic platelet transfusion threshold</h4> <p>Prophylactic platelet transfusions are typically given when blood platelet counts fall below a given trigger level. Studies have compared different platelet count thresholds to trigger the administration of prophylactic platelet transfusions. The current consensus is that people should receive a platelet transfusion when the platelet count is less than 10 x 10<sup>9</sup>/L, unless there are other risk factors for bleeding such as sepsis, concurrent use of antibiotics, or other abnormalities of haemostasis (<a href="./references#CD010983-bbs2-0165" title="British Committee for Standards in Haematology (BCSH). Guidelines for the use of platelet transfusions. British Journal of Haematology2003;122:10‐23. ">BCSH 2003</a>; <a href="./references#CD010983-bbs2-0166" title="British Committee for Standards in Haematology (BCSH). Transfusion guidelines for neonates and older children. British Journal of Haematology2004;124(4):433‐53. ">BCSH 2004</a>; <a href="./references#CD010983-bbs2-0170" title="The Board of the German Medical Association on the Recommendation of the Scientific Advisory Board. Platelet concentrates. Cross‐sectional guidelines for therapy with blood components and plasma derivatives. Transfusion Medicine and Hemotherapy2009;36:372‐82. ">Board 2009</a>; <a href="./references#CD010983-bbs2-0204" title="National Blood Authority. The National Blood Authority’s Patient Blood Management Guideline: Module 3 – Medical. National Blood Authority, 2012. ">NBA 2012</a>; <a href="./references#CD010983-bbs2-0217" title="SchifferCA , AndersonKC , BennettCL , BernsteinS , EltingLS , GoldsmithM , et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology2001;19:1519‐38. ">Schiffer 2001</a>; <a href="./references#CD010983-bbs2-0129" title="SlichterSJ . Evidence‐based platelet transfusion guidelines. Hematology/the Education Program of the American Society of Hematology2007;2007:172‐8. ">Slichter 2007</a>; <a href="./references#CD010983-bbs2-0229" title="TinmouthAT . Chapter 18: Platelet transfusion, alloimmunization and management of platelet refractoriness. Canadian Blood Services. 4th Edition. Canadian Blood Services, 2007. ">Tinmouth 2007</a>). The experimental interventions were higher or lower platelet transfusion thresholds. </p> <p>The previous review raised the issue that a platelet count of 10 x 10<sup>9</sup>/L may not be equivalent to 20 x 10<sup>9</sup>/L as previously thought (<a href="./references#CD010983-bbs2-0233" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3] ">Estcourt 2012a</a>). </p> </section> </section> <section id="CD010983-sec-0020"> <h3 class="title" id="CD010983-sec-0020">How the intervention might work</h3> <section id="CD010983-sec-0021"> <h4 class="title">Prophylactic platelet threshold</h4> <p>The morning platelet count has traditionally been used to indicate when a patient requires prophylactic platelet transfusions. It became standard practice to transfuse platelets at platelet counts below 20 x 10<sup>9</sup>/L, in an attempt to prevent bleeding (<a href="./references#CD010983-bbs2-0168" title="BeutlerE . Platelet transfusions: the 20,000/μL trigger. Blood1993;81:1411‐3. ">Beutler 1993</a>). This practice was partly based on the findings of non‐randomised studies that showed that gross haemorrhage (haematuria, haematemesis, and melaena) was present at platelet counts below 5 x 10<sup>9</sup>/L more frequently than when the platelet count was between 5 x 10<sup>9</sup>/L and 100 x 10<sup>9</sup>/L (<a href="./references#CD010983-bbs2-0190" title="GaydosLA , FreireichEJ , MantelN . The quantitative relation between platelet count and hemorrhage in patients with acute leukaemia. The New England Journal of Medicine1962;266:905‐9. ">Gaydos 1962</a>; <a href="./references#CD010983-bbs2-0221" title="SlichterSJ , HarkerLA . Thrombocytopenia: mechanisms and management of defects in platelet production. Clinical Haematology1978;7:523‐39. ">Slichter 1978</a>). However, these studies did not clearly support the use of a threshold for prophylactic platelet transfusion of 20 x 10<sup>9</sup>/L, nor was any threshold effect seen (<a href="./references#CD010983-bbs2-0190" title="GaydosLA , FreireichEJ , MantelN . The quantitative relation between platelet count and hemorrhage in patients with acute leukaemia. The New England Journal of Medicine1962;266:905‐9. ">Gaydos 1962</a>; <a href="./references#CD010983-bbs2-0221" title="SlichterSJ , HarkerLA . Thrombocytopenia: mechanisms and management of defects in platelet production. Clinical Haematology1978;7:523‐39. ">Slichter 1978</a>). A similar pattern of increased bleeding at platelet counts ≤ 5 x 10<sup>9</sup>/L was also seen in two recent RCTs (<a href="./references#CD010983-bbs2-0130" title="AssmanS , TriulziDJ , McCulloughJ , HarrisonRW , SlichterSJ . Cost tradeoffs of low‐, medium‐, and high‐dose platelet transfusions. Transfusion2013;53(Supplement):188A. JosephsonC , SloanS , GrangerS , CastillejoM , StraussRG , SlichterS , et al. Increased incidence of Grade 2 and higher bleeding in pediatric PLADO trial patients. Transfusion2009;49(S3):19A‐20A. JosephsonCD , GrangerS , AssmannSF , CastillejoM‐I , StraussRG , SlichterSJ , et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment‐induced hypoproliferative thrombocytopenia. Blood2012;120(4):748‐60. KaufmanRM , AssmannSF , TriulziDJ , StraussRG , NessP , GrangerS , et al. Transfusion‐related adverse events in the platelet dose study. Transfusion2015;55(1):144‐53. NCT00128713 . Optimal platelet dose strategy for management of thrombocytopenia. http://clinicaltrials.gov/show/NCT00128713 (accessed 16 April 2010). SlichterSJ . Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. Journal of Clinical Apheresis2006;21:78‐84. SlichterSJ , KaufmanRM , AssmanSF , BrecherME , GernsheimerT , HillyerCD , et al. Effects of prophylactic platelet (Plt) dose on transfusion (Tx) outcomes (PLADO trial). [50th Annual Meeting of the American Society of Hematology]. Blood2008;112(11):Abstract 285. SlichterSJ , KaufmanRM , AssmannSF , McCulloughJ , TriulziDJ , StraussRG , et al. Dose of prophylactic platelet transfusions and prevention of haemorrhage. The New England Journal of Medicine2010;362:600‐13. TriulziDJ , AssmannSF , StraussRG , NessPM , HessJ , GrangerS , et al. The effect of platelet characteristics on the platelet increment and HLA alloimmunization in hypoproliferative thrombocytopenia. Transfusion2010;50(Supplement):3A. TriulziDJ , AssmannSF , StraussRG , NessPM , HessJR , KaufmanRM , et al. The impact of platelet transfusion characteristics on post‐transfusion platelet increments and clinical bleeding in patients with hypo‐proliferative thrombocytopenia. Blood2012;119(23):5553‐62. ">Slichter 2010</a>; <a href="./references#CD010983-bbs2-0154" title="NCT00521664 . A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664 (accessed 4 January 2010). Schaefer‐EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):Abstract. Schaefer‐EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):Abstract. WandtH , Schaefer‐EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):Abstract. WandtH , Schaefer‐EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):Abstract. WandtH , Schaefer‐EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open‐label, multicentre, randomised study. The Lancet2012;380(9850):1309‐16. WandtH , Schäfer‐EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high‐dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , WendelinK , Schaefer‐EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>). </p> <p>The routine use of platelet transfusions in people with haematological malignancies from the 1970s resulted in a decreased mortality rate due to bleeding (less than 1% of patients) (<a href="./references#CD010983-bbs2-0222" title="SlichterSJ . Controversies in platelet transfusion therapy. Annual Reviews of Medicine1980;31:509‐40. ">Slichter 1980</a>). Despite the lack of evidence, the widespread use of a threshold platelet count of 20 x 10<sup>9</sup>/L for prophylactic platelet transfusions led to a marked growth in the demand for platelet concentrates (<a href="./references#CD010983-bbs2-0226" title="SullivanMT , McCulloughJ , SchreiberGB , WallaceEL . Blood collection and transfusion in the United States in 1997. Transfusion2002;42(10):1253‐60. ">Sullivan 2002</a>). This increased demand stimulated research to address whether the threshold could be safely lowered to 10 x 10<sup>9</sup>/L (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>, reviewed in <a href="./references#CD010983-bbs2-0235" title="StanworthSJ , HydeC , HeddleN , RebullaP , BrunskillS , MurphyMF . Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004269.pub2] ">Stanworth 2004</a>). The consensus formulated from these trials was that people should receive a platelet transfusion when the platelet count is &lt; 10 x 10<sup>9</sup>/L, unless there are other risk factors for bleeding such as sepsis, concurrent use of antibiotics, or other abnormalities of haemostasis (<a href="./references#CD010983-bbs2-0165" title="British Committee for Standards in Haematology (BCSH). Guidelines for the use of platelet transfusions. British Journal of Haematology2003;122:10‐23. ">BCSH 2003</a>; <a href="./references#CD010983-bbs2-0166" title="British Committee for Standards in Haematology (BCSH). Transfusion guidelines for neonates and older children. British Journal of Haematology2004;124(4):433‐53. ">BCSH 2004</a>; <a href="./references#CD010983-bbs2-0170" title="The Board of the German Medical Association on the Recommendation of the Scientific Advisory Board. Platelet concentrates. Cross‐sectional guidelines for therapy with blood components and plasma derivatives. Transfusion Medicine and Hemotherapy2009;36:372‐82. ">Board 2009</a>; <a href="./references#CD010983-bbs2-0204" title="National Blood Authority. The National Blood Authority’s Patient Blood Management Guideline: Module 3 – Medical. National Blood Authority, 2012. ">NBA 2012</a>; <a href="./references#CD010983-bbs2-0217" title="SchifferCA , AndersonKC , BennettCL , BernsteinS , EltingLS , GoldsmithM , et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology2001;19:1519‐38. ">Schiffer 2001</a>; <a href="./references#CD010983-bbs2-0129" title="SlichterSJ . Evidence‐based platelet transfusion guidelines. Hematology/the Education Program of the American Society of Hematology2007;2007:172‐8. ">Slichter 2007</a>; <a href="./references#CD010983-bbs2-0229" title="TinmouthAT . Chapter 18: Platelet transfusion, alloimmunization and management of platelet refractoriness. Canadian Blood Services. 4th Edition. Canadian Blood Services, 2007. ">Tinmouth 2007</a>), when the threshold should be raised. </p> <p>There have been calls for a further reduction in the threshold to 5 x 10<sup>9</sup>/L because of the previously mentioned evidence for an increased rate of bleeding at a platelet count of ≤ 5 x 10<sup>9</sup>/L (<a href="./references#CD010983-bbs2-0165" title="British Committee for Standards in Haematology (BCSH). Guidelines for the use of platelet transfusions. British Journal of Haematology2003;122:10‐23. ">BCSH 2003</a>; <a href="./references#CD010983-bbs2-0046" title="GmürJ , BurgerJ , SchanzU , FehrJ , SchaffnerA . Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. The Lancet1991;338:1223‐6. ">Gmür 1991</a>). However, a major concern in doing this is the reported inaccuracy of current automated counters when the platelet count is very low (<a href="./references#CD010983-bbs2-0193" title="HarrisonP , AultKA , ChapmanS , CharieL , DavisB , FujimotoK , et al. An interlaboratory study of a candidate reference method for platelet counting. American Journal of Clinical Pathology2001;115:448‐59. ">Harrison 2001</a>). This was well demonstrated in a large multi‐centre study of platelet analyser accuracy when measuring platelet counts &lt; 20 x 10<sup>9</sup>/L (<a href="./references#CD010983-bbs2-0219" title="SegalHC , BriggsC , KunkaS , CasbardA , HarrisonP , MachinSJ , et al. Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion. British Journal of Haematology2005;128:520‐5. ">Segal 2005</a>). </p> <p>Platelet mass has been used as a transfusion trigger for neonatal platelet transfusions (<a href="./references#CD010983-bbs2-0043" title="GerdayE , BaerVL , LambertDK , PauDA , Sola‐VisnerMC , PysherTJ , et al. Testing platelet mass versus platelet count to guide platelet transfusions in the neonatal intensive care unit. Transfusion2009;49:2034‐9. ">Gerday 2009</a>). Different platelet count thresholds have been the only known trigger used in people with a haematological disorder. </p> </section> <section id="CD010983-sec-0022"> <h4 class="title">Assessment of bleeding</h4> <p>A bleeding assessment has been seen as a more clinically relevant measure of the effect of platelet transfusions than surrogate markers such as the platelet increment. </p> <p>Any review that uses bleeding as a primary outcome measure needs to assess the way that the trials have recorded bleeding. Unfortunately, the way bleeding has been recorded and assessed has varied markedly between trials (<a href="./references#CD010983-bbs2-0177" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomized trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. ">Cook 2004</a>; <a href="./references#CD010983-bbs2-0183" title="EstcourtLJ , HeddleN , KaufmanRM , McCulloughJ , MurphyMF , SlichterS , et al. On behalf of the BEST (Biomedical Excellence for Safer Transfusion) Collaborative. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion2013;53(7):1531‐43. ">Estcourt 2013</a>; <a href="./references#CD010983-bbs2-0061" title="HeddleNM , CookRJ , WebertKE , SigouinC , RebullaP . Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion2003;43:742‐52. ">Heddle 2003</a>). </p> <p>Retrospective analysis of bleeding leads to a risk of bias because bleeding events may be missed, and only more severe bleeding is likely to have been documented. Prospective bleeding assessment forms provide more information and are less likely to miss bleeding events. However, different assessors may grade the same bleed differently, and it is very difficult to blind the assessor to the intervention. </p> <p>The majority of trials have used the WHO system, or a modification of it, for grading bleeding (<a href="./references#CD010983-bbs2-0183" title="EstcourtLJ , HeddleN , KaufmanRM , McCulloughJ , MurphyMF , SlichterS , et al. On behalf of the BEST (Biomedical Excellence for Safer Transfusion) Collaborative. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion2013;53(7):1531‐43. ">Estcourt 2013</a>; <a href="./references#CD010983-bbs2-0201" title="KorethR , WeinertC , WeisdorfDJ , KeyNS . Measurement of bleeding severity: a critical review. Transfusion2004;44:605‐17. ">Koreth 2004</a>; <a href="./references#CD010983-bbs2-0231" title="World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset publication No. 48. Geneva: World Health Organization, 1979. ">WHO 1979</a>). One limitation of all the scoring systems based on the WHO system is that the categories are relatively broad and subjective, meaning that a small change in a participant's bleeding risk may not be detected. Another limitation is that the modified WHO categories are partially defined by whether a bleeding participant requires a blood transfusion. The threshold for intervention may vary between clinicians and institutions, and so the same level of bleeding may be graded differently in different institutions. </p> <p>The definition of what constitutes clinically significant bleeding has varied between studies. Although the majority of more recent platelet transfusion studies have classified it as WHO Grade 2 or above (<a href="./references#CD010983-bbs2-0195" title="HeddleNM , CookRJ , TinmouthA , KouroukisCT , HervigT , KlapperE , et al. A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood2009;113(7):1564‐73. ">Heddle 2009a</a>; <a href="./references#CD010983-bbs2-0130" title="AssmanS , TriulziDJ , McCulloughJ , HarrisonRW , SlichterSJ . Cost tradeoffs of low‐, medium‐, and high‐dose platelet transfusions. Transfusion2013;53(Supplement):188A. JosephsonC , SloanS , GrangerS , CastillejoM , StraussRG , SlichterS , et al. Increased incidence of Grade 2 and higher bleeding in pediatric PLADO trial patients. Transfusion2009;49(S3):19A‐20A. JosephsonCD , GrangerS , AssmannSF , CastillejoM‐I , StraussRG , SlichterSJ , et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment‐induced hypoproliferative thrombocytopenia. Blood2012;120(4):748‐60. KaufmanRM , AssmannSF , TriulziDJ , StraussRG , NessP , GrangerS , et al. Transfusion‐related adverse events in the platelet dose study. Transfusion2015;55(1):144‐53. NCT00128713 . Optimal platelet dose strategy for management of thrombocytopenia. http://clinicaltrials.gov/show/NCT00128713 (accessed 16 April 2010). SlichterSJ . Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. Journal of Clinical Apheresis2006;21:78‐84. SlichterSJ , KaufmanRM , AssmanSF , BrecherME , GernsheimerT , HillyerCD , et al. Effects of prophylactic platelet (Plt) dose on transfusion (Tx) outcomes (PLADO trial). [50th Annual Meeting of the American Society of Hematology]. Blood2008;112(11):Abstract 285. SlichterSJ , KaufmanRM , AssmannSF , McCulloughJ , TriulziDJ , StraussRG , et al. Dose of prophylactic platelet transfusions and prevention of haemorrhage. The New England Journal of Medicine2010;362:600‐13. TriulziDJ , AssmannSF , StraussRG , NessPM , HessJ , GrangerS , et al. The effect of platelet characteristics on the platelet increment and HLA alloimmunization in hypoproliferative thrombocytopenia. Transfusion2010;50(Supplement):3A. TriulziDJ , AssmannSF , StraussRG , NessPM , HessJR , KaufmanRM , et al. The impact of platelet transfusion characteristics on post‐transfusion platelet increments and clinical bleeding in patients with hypo‐proliferative thrombocytopenia. Blood2012;119(23):5553‐62. ">Slichter 2010</a>; <a href="./references#CD010983-bbs2-0224" title="StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163‐71. ">Stanworth 2010</a>; <a href="./references#CD010983-bbs2-0154" title="NCT00521664 . A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664 (accessed 4 January 2010). Schaefer‐EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):Abstract. Schaefer‐EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):Abstract. WandtH , Schaefer‐EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):Abstract. WandtH , Schaefer‐EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):Abstract. WandtH , Schaefer‐EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open‐label, multicentre, randomised study. The Lancet2012;380(9850):1309‐16. WandtH , Schäfer‐EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high‐dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , WendelinK , Schaefer‐EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>), in the past there has been greater heterogeneity (<a href="./references#CD010983-bbs2-0177" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomized trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. ">Cook 2004</a>; <a href="./references#CD010983-bbs2-0183" title="EstcourtLJ , HeddleN , KaufmanRM , McCulloughJ , MurphyMF , SlichterS , et al. On behalf of the BEST (Biomedical Excellence for Safer Transfusion) Collaborative. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion2013;53(7):1531‐43. ">Estcourt 2013</a>; <a href="./references#CD010983-bbs2-0201" title="KorethR , WeinertC , WeisdorfDJ , KeyNS . Measurement of bleeding severity: a critical review. Transfusion2004;44:605‐17. ">Koreth 2004</a>). The difficulties of assessing and grading bleeding may limit the ability to compare results between studies, and this needs to be kept in mind when reviewing the evidence for the effectiveness of prophylactic platelet transfusions at different doses. </p> </section> </section> <section id="CD010983-sec-0023"> <h3 class="title" id="CD010983-sec-0023">Why it is important to do this review</h3> <p>Although considerable advances have been made in platelet transfusion therapy in the last 40 years, 3 major areas continue to provoke debate. </p> <p> <ul id="CD010983-list-0001"> <li> <p>Firstly, what is the optimal prophylactic platelet dose to prevent thrombocytopenic bleeding? </p> </li> <li> <p>Secondly, which threshold should be used to trigger the transfusion of prophylactic platelets? </p> </li> <li> <p>Thirdly, are prophylactic platelet transfusions superior to therapeutic platelet transfusions for the prevention or control of life‐threatening thrombocytopenic bleeding? </p> </li> </ul> </p> <p>The initial formulation of this Cochrane review attempted to answer these questions, but the evidence at the time was insufficient for us to draw any definitive conclusions (<a href="./references#CD010983-bbs2-0235" title="StanworthSJ , HydeC , HeddleN , RebullaP , BrunskillS , MurphyMF . Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004269.pub2] ">Stanworth 2004</a>). This review was updated (<a href="./references#CD010983-bbs2-0233" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3] ">Estcourt 2012a</a>). For clarity and simplicity, we have now split the review to answer each question separately. </p> <p>This review focuses solely on the second question: Which threshold should be used to trigger the transfusion of prophylactic platelets? </p> <p>Avoiding the need for unnecessary prophylactic platelet transfusions in people with haematological disorders will have significant logistical and financial implications for national health services as well as decreasing patients' exposure to the risks of transfusion. These factors are perhaps even more important in the development of platelet transfusion strategies in low‐income countries, where access to blood components is much more limited than in high‐income countries (<a href="./references#CD010983-bbs2-0230" title="VermaA , AgarwalP . Platelet utilization in the developing world: strategies to optimize platelet transfusion practices. Transfusion and Apheresis Science2009;41(2):145‐9. ">Verma 2009</a>). </p> <p>This review did not assess the evidence for the answers to the other two questions, as these are the focus of separate Cochrane reviews, nor did it assess the use of alternative agents instead of prophylactic platelet transfusions because this is the focus of another review. </p> <p>This review did not assess whether there are any differences in the efficacy of apheresis versus whole‐blood derived platelet products, the efficacy of pathogen‐reduced platelet components, the efficacy of human leukocyte antigen (HLA)‐matched versus random‐donor platelets, or differences between ABO identical and ABO non‐identical platelet transfusions, as recent systematic reviews have covered these topics (<a href="./references#CD010983-bbs2-0173" title="ButlerC , DoreeC , EstcourtLJ , TrivellaM , HopewellS , BrunskillSJ , et al. Pathogen‐reduced platelets for the prevention of bleeding. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD009072] ">Butler 2013</a>; <a href="./references#CD010983-bbs2-0194" title="HeddleNM , ArnoldDM , BoyeD , WebertKE , ReszI , DumontLJ . Comparing the efficacy and safety of apheresis and whole blood‐derived platelet transfusions: a systematic review. Transfusion2008;48(7):1447‐58. ">Heddle 2008</a>; <a href="./references#CD010983-bbs2-0209" title="PavenskiK , RebullaP , DuquesnoyR , SawCL , SlichterSJ , TanaelS , et al. International Collaboration for Guideline Development, Implementation. Evaluation for TransfusionTherapies , Collaborators. Efficacy of HLA‐matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion2013;53:2230‐42. [DOI: 10.1111/trf.12175] ">Pavenski 2013</a>; <a href="./references#CD010983-bbs2-0120" title="ShehataN , TinmouthA , NaglieG , FreedmanJ , WilsonK . ABO‐identical versus non‐identical platelet transfusion: a systematic review. Transfusion2009;49:2442‐53. ">Shehata 2009</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010983-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010983-sec-0024"></div> <p>To determine whether different platelet transfusion thresholds for administration of prophylactic platelet transfusions (platelet transfusions given to prevent bleeding) affect the efficacy and safety of prophylactic platelet transfusions in preventing bleeding in people with haematological disorders undergoing myelosuppressive chemotherapy or haematopoietic stem cell transplantation (HSCT). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010983-sec-0025" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010983-sec-0025"></div> <section id="CD010983-sec-0026"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010983-sec-0027"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) in this review irrespective of language or publication status. </p> </section> <section id="CD010983-sec-0028"> <h4 class="title">Types of participants</h4> <p>People with haematological disorders receiving treatment with myelosuppressive chemotherapy or stem cell transplantation, or both. We included people of all ages, in both inpatient and outpatient clinical settings. If trials consisted of mixed populations of patients (for example people with diagnoses of solid tumours), we used only data from the haematological subgroups. If subgroup data for haematological patients were not provided (after contacting the authors of the trial), we excluded the trial if fewer than 80% of participants had a haematological disorder. We excluded any participants who were not being treated with intensive chemotherapy or a stem cell transplant. We included participants with non‐malignant haematological disorders (for example aplastic anaemia, congenital bone marrow failure syndromes) who were being treated with an allogeneic stem cell transplant. These participants would be expected to be thrombocytopenic during pre‐transplant conditioning therapy and during the transplantation period, requiring platelet transfusion support. </p> </section> <section id="CD010983-sec-0029"> <h4 class="title">Types of interventions</h4> <p>Participants received transfusions of platelet concentrates, prepared either from individual units of whole blood or by apheresis, and given prophylactically to prevent bleeding. Prophylactic platelet transfusions are typically given when blood platelet counts fall below a given trigger level. There was no restriction on dose or frequency of platelet transfusion or the type of platelet component, but we took this information into account in the analysis, where available. </p> <p>We included the following comparisons:</p> <p> <ul id="CD010983-list-0002"> <li> <p>Lower platelet count threshold (5 x 10<sup>9</sup>/L) versus standard platelet transfusion threshold (10 x 10<sup>9</sup>/L). </p> </li> <li> <p>Higher platelet count threshold (20 x 10<sup>9</sup>/L, 30 x 10<sup>9</sup>/L, or 50 x 10<sup>9</sup>/L) versus standard platelet transfusion threshold (10 x 10<sup>9</sup>/L). </p> </li> <li> <p>Different platelet count thresholds (5 x 10<sup>9</sup>/L, 20 x 10<sup>9</sup>/L, 30 x 10<sup>9</sup>/L, or 50 x 10<sup>9</sup>/L) that do not include a comparison against the standard platelet transfusion threshold (10 x 10<sup>9</sup>/L). </p> </li> <li> <p>Alternative thresholds to guide prophylactic platelet transfusions (e.g. platelet mass, immature platelet fraction, absolute immature platelet number). As there are currently no standard thresholds used for these alternative platelet measures, we planned to use the study's own thresholds for these alternative measures. </p> </li> </ul> </p> </section> <section id="CD010983-sec-0030"> <h4 class="title">Types of outcome measures</h4> <section id="CD010983-sec-0031"> <h5 class="title">Primary outcomes</h5> <p>Number and severity of bleeding episodes during the first 30 days of the study:</p> <p> <ol id="CD010983-list-0003"> <li> <p>The number of participants with at least one bleeding episode.</p> </li> <li> <p>The total number of days on which bleeding occurred.</p> </li> <li> <p>Number of participants with at least one episode of severe or life‐threatening haemorrhage.</p> </li> <li> <p>Time to first bleeding episode from the start of study.</p> </li> </ol> </p> </section> <section id="CD010983-sec-0032"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010983-list-0004"> <li> <p>Mortality (all‐causes, secondary to bleeding, and secondary to infection) within 30 and 90 days from the start of the study. </p> </li> <li> <p>Number of platelet transfusions per participant and number of platelet components per participant within 30 days from the start of the study. </p> </li> <li> <p>Number of red cell transfusions per participant and number of red cell components per participant within 30 days from the start of the study. </p> </li> <li> <p>Platelet transfusion interval within 30 days from the start of the study.</p> </li> <li> <p>Proportion of participants requiring additional interventions to stop bleeding (surgical, medical e.g. tranexamic acid, other blood products e.g. fresh frozen plasma (FFP), cryoprecipitate). </p> </li> <li> <p>Overall survival within 30, 90, and 180 days from the start of the study.</p> </li> <li> <p>Proportion of participants achieving complete remission within 30 and 90 days from the start of the study. </p> </li> <li> <p>Total time in hospital within 30 days from the start of the study.</p> </li> <li> <p>Adverse effects of treatments (transfusion reactions, thromboembolism, transfusion‐transmitted infection, development of platelet antibodies, development of platelet refractoriness) within 30 days from the start of the study. </p> </li> <li> <p>Quality of life, as defined by the individual studies.</p> </li> </ol> </p> <p>We expressed all primary and secondary outcomes in the formats defined in the <a href="#CD010983-sec-0050">Measures of treatment effect</a> section of this protocol if data were available, except for two of our outcomes that we planned to be only narrative reports. </p> <p>These were:</p> <p> <ul id="CD010983-list-0005"> <li> <p>Platelet transfusion interval, as it can be calculated in many different ways and it was unlikely that the exact methodology would be reported sufficiently to allow us to combine the data. </p> </li> <li> <p>Assessment of quality of life (QoL). We planned to use the study's own measure, as there is no definitive patient‐reported outcome measure for this patient group (<a href="./references#CD010983-bbs2-0187" title="EstcourtLJ , PinchonD , SymingtonE , KellyAM , DoreeC , BrunskillS , et al. Does bleeding affect patient reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review. Transfusion2014;54(4):1166‐79. [DOI: 10.1111/trf.12441] ">Estcourt 2014e</a>). </p> </li> </ul> </p> <p>However, none of the included studies reported either of these outcomes.</p> </section> </section> </section> <section id="CD010983-sec-0033"> <h3 class="title">Search methods for identification of studies</h3> <p>The Systematic Review Initiative (SRI) Information Specialist (CD) formulated new search strategies in collaboration with the Cochrane Haematological Malignancies Review Group based on those used in previous versions of this review (<a href="./references#CD010983-bbs2-0233" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3] ">Estcourt 2012a</a>; <a href="./references#CD010983-bbs2-0235" title="StanworthSJ , HydeC , HeddleN , RebullaP , BrunskillS , MurphyMF . Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004269.pub2] ">Stanworth 2004</a>). </p> <section id="CD010983-sec-0034"> <h4 class="title">Electronic searches</h4> <section id="CD010983-sec-0035"> <h5 class="title">Bibliographic databases</h5> <p>We searched for RCTs in the following databases:</p> <p> <ul id="CD010983-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library 2015, Issue 6, 23 July 2015) (<a href="./appendices#CD010983-sec-0126">Appendix 1</a>) </p> </li> <li> <p>MEDLINE (OvidSP, 1946 to 23 July 2015) (<a href="./appendices#CD010983-sec-0127">Appendix 2</a>) </p> </li> <li> <p>PubMed (epublications only to 23 July 2015) (<a href="./appendices#CD010983-sec-0128">Appendix 3</a>) </p> </li> <li> <p>Embase (OvidSp, 1974 to the 23 July 2015) (<a href="./appendices#CD010983-sec-0129">Appendix 4</a>) </p> </li> <li> <p>CINAHL (EBSCOhost, 1937 to 23 July 2015) (<a href="./appendices#CD010983-sec-0130">Appendix 5</a>) </p> </li> <li> <p>UKBTS/SRI Transfusion Evidence Library (<a href="http://www.transfusionevidencelibrary.com" target="_blank">www.transfusionevidencelibrary.com</a>) (1950 to 23 July 2015) (<a href="./appendices#CD010983-sec-0131">Appendix 6</a>) </p> </li> <li> <p>Web of Science: Conference Proceedings Citation Index‐Science (CPCI‐S) (Thomson Reuters, 1990 to 23 July 2015) (<a href="./appendices#CD010983-sec-0132">Appendix 7</a>) </p> </li> <li> <p>LILACS (BIREME/PAHO/WHO, 1982 to to 23 July 2015) (<a href="./appendices#CD010983-sec-0133">Appendix 8</a>) </p> </li> <li> <p>IndMed (ICMR‐NIC, 1985 to 23 July 2015) (<a href="./appendices#CD010983-sec-0134">Appendix 9</a>) </p> </li> <li> <p>KoreaMed (KAMJE, 1997 to 23 July 2015) (<a href="./appendices#CD010983-sec-0135">Appendix 10</a>) </p> </li> <li> <p>PakMediNet (2001 to 23 July 2015) (<a href="./appendices#CD010983-sec-0135">Appendix 10</a>) </p> </li> </ul> </p> <p>We updated searches from the original search in January 2002, <a href="./references#CD010983-bbs2-0235" title="StanworthSJ , HydeC , HeddleN , RebullaP , BrunskillS , MurphyMF . Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004269.pub2] ">Stanworth 2004</a>, and the updated search on 10 November 2011 (<a href="./references#CD010983-bbs2-0233" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3] ">Estcourt 2012a</a>). We combined searches in MEDLINE, Embase, and CINAHL with adaptations of the Cochrane RCT search filters, as detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010983-bbs2-0203" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>). We did not limit searches by language or publication status. </p> </section> <section id="CD010983-sec-0036"> <h5 class="title">Databases of ongoing trials</h5> <p>We also searched ClinicalTrials.gov (<a href="http://clinicaltrials.gov/ct2/search" target="_blank">http://clinicaltrials.gov/ct2/search</a>) (<a href="./appendices#CD010983-sec-0136">Appendix 11</a>), the WHO International Clinical Trials Registry (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>) (<a href="./appendices#CD010983-sec-0136">Appendix 11</a>), the ISRCTN Register (<a href="http://www.controlled-trials.com/isrctn/" target="_blank">http://www.controlled‐trials.com/isrctn/</a>) (<a href="./appendices#CD010983-sec-0137">Appendix 12</a>), the EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/ctr-search" target="_blank">https://www.clinicaltrialsregister.eu/ctr‐search</a>) (<a href="./appendices#CD010983-sec-0137">Appendix 12</a>), and the Hong Kong Clinical Trials Register (<a href="http://www.hkclinicaltrials.com/" target="_blank">http://www.hkclinicaltrials.com/</a>) (<a href="./appendices#CD010983-sec-0138">Appendix 13</a>) in order to identify ongoing trials to 23 July 2015. </p> <p>All new search strategies are presented as indicated in <a href="#CD010983-sec-0125">Appendices</a> 1 to 13. Search strategies for both the original (2002) and update (2011) searches are presented in <a href="./appendices#CD010983-sec-0139">Appendix 14</a>. </p> </section> </section> <section id="CD010983-sec-0037"> <h4 class="title">Searching other resources</h4> <p>We augmented database searching with the following.</p> <section id="CD010983-sec-0038"> <h5 class="title">Handsearching of reference lists</h5> <p>We checked references of all included trials, relevant review articles, and current treatment guidelines for further literature. We limited these searches to the 'first generation' reference lists. </p> </section> <section id="CD010983-sec-0039"> <h5 class="title">Personal contacts</h5> <p>We contacted authors of relevant studies, study groups, and experts worldwide known to be active in the field for unpublished material or further information on ongoing studies. </p> </section> </section> </section> <section id="CD010983-sec-0040"> <h3 class="title" id="CD010983-sec-0040">Data collection and analysis</h3> <section id="CD010983-sec-0041"> <h4 class="title">Selection of studies</h4> <p>We updated the selection of studies from the selection of studies performed for the previous version of this review (<a href="./references#CD010983-bbs2-0233" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3] ">Estcourt 2012a</a>). </p> <p>Two out of three independent review authors (LE, PB, and CD) initially screened all electronically derived citations and abstracts of papers identified by the review search strategy for relevance. We excluded studies clearly irrelevant at this stage. </p> <p>Two independent review authors (LE, PB) then formally assessed the full texts of all potentially relevant trials for eligibility against the criteria outlined above. We resolved all disagreements by discussion without the need to consult a third review author (SS). We sought further information from study authors if an article contained insufficient data to make a decision about eligibility. We designed a study eligibility form for trials of platelet transfusion to help in the assessment of relevance, which included ascertaining whether the participants had haematological disorders and whether the two groups could be defined in the trial on the basis of differences in use of prophylactic platelet transfusion doses. We recorded the reasons why potentially relevant studies failed to meet the eligibility criteria. </p> </section> <section id="CD010983-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>We updated the data extraction from the data extraction performed for the previous version of this review, <a href="./references#CD010983-bbs2-0233" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3] ">Estcourt 2012a</a>, to include new review outcomes that were not part of the previous review (for example platelet transfusion interval, quality of life). We identified no new studies in this updated review. </p> <p>Two review authors (LE, SS) conducted data extraction according to the guidelines proposed by The Cochrane Collaboration (<a href="./references#CD010983-bbs2-0197" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). Any disagreements between the review authors were resolved by consensus. The review authors were not blinded to names of authors, institutions, journals, or the outcomes of the trials. The data extraction forms had been piloted in the previous version of this review (<a href="./references#CD010983-bbs2-0233" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3] ">Estcourt 2012a</a>). Due to minor changes in the format, we piloted the forms on a further study; thereafter the two review authors (LE, SS) independently extracted data for all the studies. We extracted the following data. </p> <section id="CD010983-sec-0043"> <h5 class="title">General information</h5> <p>Review author's name, date of data extraction, study ID, first author of study, author's contact address (if available), citation of paper, objectives of the trial.  </p> </section> <section id="CD010983-sec-0044"> <h5 class="title">Trial details</h5> <p>Trial design, location, setting, sample size, power calculation, treatment allocation, randomisation, blinding, inclusion and exclusion criteria, reasons for exclusion, comparability of groups, length of follow‐up, stratification, stopping rules described, statistical analysis, results, conclusion, and funding. </p> </section> <section id="CD010983-sec-0045"> <h5 class="title">Characteristics of participants</h5> <p>Age, gender, ethnicity, total number recruited, total number randomised, total number analysed, types of haematological disease, lost to follow‐up numbers, dropouts (percentage in each arm) with reasons, protocol violations, previous treatments, current treatment, prognostic factors. </p> </section> <section id="CD010983-sec-0046"> <h5 class="title">Interventions</h5> <p>Experimental and control interventions, type of platelet given, timing of intervention, dosage of platelet given, compliance to interventions, additional interventions given especially in relation to red cell transfusions, any differences between interventions. </p> </section> <section id="CD010983-sec-0047"> <h5 class="title">Assessment of bias</h5> <p>Sequence generation, allocation concealment, blinding (participants, personnel, and outcome assessors), incomplete outcome data, selective outcome reporting, other sources of bias. </p> </section> <section id="CD010983-sec-0048"> <h5 class="title">Outcomes measured</h5> <p>Number and severity of bleeding episodes. Mortality (all causes), and mortality due to bleeding. Overall survival. Proportion of participants achieving complete remission. Time in hospital. Number of platelet transfusions and platelet components. Number of red cell transfusions and red cell components. Platelet transfusion interval. Proportion of participants requiring additional interventions to stop bleeding (surgical, medical such as tranexamic acid, other blood products such as fresh frozen plasma (FFP), cryoprecipitate). Quality of life. Adverse effects of treatments (for example transfusion reactions, thromboembolism, transfusion‐transmitted infection, development of platelet antibodies or platelet refractoriness). </p> <p>We used both full‐text versions and abstracts to retrieve the data. We extracted publications reporting on more than one trial using one data extraction form for each trial. We extracted trials reported in more than one publication on one form only. When these sources provided insufficient information, we contacted the authors and study groups for additional details. </p> <p>One review author performed data entry into software, which a second review author checked for accuracy. </p> </section> </section> <section id="CD010983-sec-0049"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We updated the 'Risk of bias' assessment to include study funding from the 'Risk of bias' assessment performed for the previous version of this review (<a href="./references#CD010983-bbs2-0233" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3] ">Estcourt 2012a</a>). </p> <p>The assessment included information about the design, conduct, and analysis of the trial. We evaluated each criterion on a three‐point scale: low risk of bias, high risk of bias, or unclear (<a href="./references#CD010983-bbs2-0199" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011c</a>). To assess risk of bias, we addressed the following questions in the 'Risk of bias' table for each included study: </p> <p> <ul id="CD010983-list-0007"> <li> <p>Was the allocation sequence adequately generated?</p> </li> <li> <p>Was allocation adequately concealed?</p> </li> <li> <p>Was knowledge of the allocated intervention adequately prevented during the study (including an assessment of blinding of participants, personnel, and outcome assessors)? </p> </li> <li> <p>Were incomplete outcome data adequately addressed (for every outcome separately)?</p> </li> <li> <p>Are reports of the study free of selective outcome reporting?</p> </li> <li> <p>Was the study apparently free of other problems that could put it at risk of bias? This included assessing whether protocol deviation was balanced between treatment arms. </p> </li> </ul> </p> </section> <section id="CD010983-sec-0050"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we recorded the number of outcomes in the treatment and control groups and estimated the treatment effect measures across individual studies as the relative effect measures (risk ratio with 95% confidence intervals (CIs)). </p> <p>For continuous outcomes, we recorded the mean and standard deviations. For continuous outcomes measured using the same scale, the effect measure was the mean difference with 95% CIs, or the standardised mean difference for outcomes measured using different scales. For time‐to‐event outcomes, we extracted the hazard ratio from published data according to <a href="./references#CD010983-bbs2-0206" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a> and <a href="./references#CD010983-bbs2-0228" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007; Vol. 8, issue 16. [DOI: 10.1186/1745‐6215‐8‐16] ">Tierney 2007</a>. </p> <p>We did not report the number needed to treat to benefit with CIs and the number needed to treat to harm with CIs because there were no differences between any of the bleeding outcomes. </p> <p>If we could not report the available data in any of the formats described above, we performed a narrative report. </p> </section> <section id="CD010983-sec-0051"> <h4 class="title">Unit of analysis issues</h4> <p>We did not prespecify in the protocol how we would deal with any unit of analysis issues. There was a unit of analysis issue for this review for the total number of days of bleeding. We only reported the number of days of bleeding if it had been reported per participant or if an appropriate analysis had been performed by the authors to account for repeated measures. In this review, the <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a> authors used a permutation analysis to take into account the repeated events data (<a href="./references#CD010983-bbs2-0189" title="FreedmanL , SylvesterR , ByarDP . Using permutation tests and bootstrap confidence limits to analyze repeated events data from clinical trials. Controlled Clinical Trials1989;10:129‐41. ">Freedman 1989</a>). All other studies had not taken into account unit of analysis issues with this outcome and data were not reported. </p> </section> <section id="CD010983-sec-0052"> <h4 class="title">Dealing with missing data</h4> <p>We dealt with missing data according to the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010983-bbs2-0198" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). We contacted four authors to obtain information that was missing or unclear in the published report. Two authors supplied missing data (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). </p> <p>In trials that included people with haematological disorders as well as people with solid tumours or non‐malignant haematological disorders, we extracted data for the malignant haematology subgroup from the general trial data. We could not do this in one study (<a href="./references#CD010983-bbs2-0163" title="ZumbergMS , RosarioML , PollockBH , NejameCF , AllenLS , BoyetteR , et al. A prospective randomized trial of prophylactic platelet transfusion d bleeding incidence in hematopoietic stem cell transplant (HSCT) recipients: 10,000µL vs. an 20,000 µL threshold [abstract]. 37th Annual Meeting of the American Society of Clinical Oncology, 2001 May 12‐15; San Fransisco. San Francisco: American Society of Clinical Oncology, 2001. ZumbergMS , delRoarioML , NejameCF , PollockBH , GarzarellaL , KaoKJ , et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/µL versus 20,000/µL trigger. Biology of Blood and Marrow Transplantation2002;8:569‐76. ">Zumberg 2002</a>); we contacted the authors, but they no longer had access to the original data, and the original reports did not provide subgroup data. We therefore excluded this study from the review. </p> <p>Within an outcome, the preferred analysis was an intention‐to‐treat analysis. When data were missing, we recorded the number of participants lost to follow‐up for each trial. </p> </section> <section id="CD010983-sec-0053"> <h4 class="title">Assessment of heterogeneity</h4> <p>If we considered studies to be sufficiently homogenous in their study design, we conducted a meta‐analysis and assessed the statistical heterogeneity (<a href="./references#CD010983-bbs2-0179" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). We assessed statistical heterogeneity of treatment effects between trials using a Chi<sup>2</sup> test with a significance level at P &lt; 0.1. We used the I<sup>2</sup> statistic to quantify heterogeneity (I<sup>2</sup> &gt; 50% moderate heterogeneity, I<sup>2</sup> &gt; 80% considerable heterogeneity). We explored potential causes of heterogeneity by sensitivity and subgroup analyses where possible. </p> </section> <section id="CD010983-sec-0054"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not perform a formal assessment of potential publication bias (small‐trial bias) because we included only three studies in this review (<a href="./references#CD010983-bbs2-0225" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Sterne 2011</a>). </p> </section> <section id="CD010983-sec-0055"> <h4 class="title">Data synthesis</h4> <p>We performed analyses according to the recommendations of The Cochrane Collaboration (<a href="./references#CD010983-bbs2-0179" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). We used aggregated data for analysis. For statistical analysis, we entered data into <a href="./references#CD010983-bbs2-0214" title="The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.3. Copenhagen: The Cochrane Collaboration, 2014. ">Review Manager 5.3</a>. </p> <p>Where meta‐analysis was feasible, we used the fixed‐effect model for pooling the data. We used the Mantel‐Haenszel method for dichotomous outcomes, and the inverse‐variance method for continuous outcomes. We used the generic inverse‐variance method for time‐to‐event outcomes. </p> <p>We used the random‐effects model for sensitivity analyses as part of the exploration of heterogeneity. If we found heterogeneity, as expressed by the I<sup>2</sup>, to be above 50%, we reported both the fixed‐effect and random‐effects models. If we found heterogeneity to be above 80%, we did not perform a meta‐analysis and commented on results as a narrative. </p> <section id="CD010983-sec-0056"> <h5 class="title">Summary of findings tables</h5> <p>We used <a href="./references#CD010983-bbs2-0191" title="McMaster University. GRADEpro [www.gradepro.org]. McMaster University, 2015. ">GRADE 2014</a> to create 'Summary of findings' tables as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010983-bbs2-0218" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). This included the number and severity of bleeding episodes within 30 days from the start of the study (number of participants with at least one bleeding episode; number of days on which bleeding occurred; number of participants with severe or life‐threatening bleeding; time to first bleeding episode), number of platelet transfusions within 30 days from the start of the study, 30‐day mortality, and quality of life. </p> </section> </section> <section id="CD010983-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We considered performing subgroup analysis on the following characteristics, if appropriate:</p> <p> <ul id="CD010983-list-0008"> <li> <p>Presence of fever (&gt; 38°C).</p> </li> <li> <p>Underlying disease.</p> </li> <li> <p>Type of treatment (autologous haematopoietic stem cell transplantation (HSCT), allogeneic HSCT, or chemotherapy alone). </p> </li> <li> <p>Age of the participant (paediatric, adults, older adults (&gt; 60 years)).</p> </li> </ul> </p> <p>We did not perform two subgroup analyses due to lack of data; these were presence of fever and type of treatment. </p> <p>We did not perform meta‐regression because no subgroup contained more than 10 studies (<a href="./references#CD010983-bbs2-0179" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). We commented on differences between subgroups as a narrative. </p> <p>Investigation of heterogeneity between studies also included, if appropriate:</p> <p> <ul id="CD010983-list-0009"> <li> <p>Age of the study (as the type of platelet component has changed over the last 40 years).</p> </li> <li> <p>Different platelet component doses.</p> </li> </ul> </p> <p>We did not assess age of study as a reason for heterogeneity, as all studies recruited participants between 1991 and 2001. </p> </section> <section id="CD010983-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We had intended to assess the robustness of our findings by the following two sensitivity analyses: </p> <p> <ul id="CD010983-list-0010"> <li> <p>Including only those trials at low risk of bias.</p> </li> <li> <p>Including only those trials in which 20% of participants or less were lost to follow‐up.</p> </li> </ul> </p> <p>All trials were at risk of bias because none of the three included RCTs blinded investigators to the intervention. </p> <p>None of the three included trials had more than 20% of participants lost to follow‐up.</p> <p>We therefore did not perform these two pre‐planned sensitivity analyses.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010983-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010983-sec-0059"></div> <section id="CD010983-sec-0060"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD010983-sec-0150" title="">Characteristics of included studies</a> and <a href="./references#CD010983-sec-0151" title="">Characteristics of excluded studies</a>; there were no ongoing studies. </p> <section id="CD010983-sec-0061"> <h4 class="title">Results of the search</h4> <p>See PRISMA flow diagram (<a href="#CD010983-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010983-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010983-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>The original search (conducted January 2002) identified a total of 3196 potentially relevant records. There were 2380 records after duplicates were removed, and 2343 records were excluded on the basis of the abstract. The original systematic review identified 37 studies that appeared relevant on the basis of their full text or abstract using the original inclusion/exclusion criteria (<a href="./references#CD010983-bbs2-0235" title="StanworthSJ , HydeC , HeddleN , RebullaP , BrunskillS , MurphyMF . Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004269.pub2] ">Stanworth 2004</a>).This was performed by one review author. </p> <p>The updated search for the previous review (conducted November 2011) identified a total of 2622 potentially relevant records. There were 2054 records after duplicates were removed, and two review authors excluded 1865 records on the basis of the abstract. We retrieved 152 full‐text articles for relevance. Two review authors (LE, SS) reviewed these full‐text articles and those from the original review (a total of 189 records) (<a href="./references#CD010983-bbs2-0233" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3] ">Estcourt 2012a</a>). </p> <p>The latest update of the search (conducted 23 July 2015) identified a total of 4923 potentially relevant records. There were 3925 records after duplicates were removed. Two review authors (LE, SS) were able to exclude 3896 records on the basis of the abstract. Two review authors (LE, SS) retrieved for relevance and reviewed 29 full‐text articles. </p> </section> <section id="CD010983-sec-0062"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD010983-sec-0150" title="">Characteristics of included studies</a> for full details of each study. </p> <section id="CD010983-sec-0063"> <h5 class="title">Ongoing studies</h5> <p>This update of the review identified no ongoing studies that were eligible for inclusion.</p> </section> <section id="CD010983-sec-0064"> <h5 class="title">Studies contributing to the main outcome</h5> <p>The three RCTs (9 publications) were published between 1997 and 2005. There were six secondary citations of included studies (cited as secondary references for the relevant included studies). </p> <p>There were no new studies. The three included studies, <a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>, <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>, and <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>, were identified in the previous version of this review (<a href="./references#CD010983-bbs2-0233" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3] ">Estcourt 2012a</a>). One study that had been included in the original review, <a href="./references#CD010983-bbs2-0235" title="StanworthSJ , HydeC , HeddleN , RebullaP , BrunskillS , MurphyMF . Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004269.pub2] ">Stanworth 2004</a>, was excluded in the previous version of this review, <a href="./references#CD010983-bbs2-0233" title="EstcourtL , StanworthSJ , DoreeC , HopewellS , MurphyMF , TinmouthA , et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3] ">Estcourt 2012a</a>, because fewer than 80% of participants had a haematological disorder, and no subgroup data could be identified (<a href="./references#CD010983-bbs2-0163" title="ZumbergMS , RosarioML , PollockBH , NejameCF , AllenLS , BoyetteR , et al. A prospective randomized trial of prophylactic platelet transfusion d bleeding incidence in hematopoietic stem cell transplant (HSCT) recipients: 10,000µL vs. an 20,000 µL threshold [abstract]. 37th Annual Meeting of the American Society of Clinical Oncology, 2001 May 12‐15; San Fransisco. San Francisco: American Society of Clinical Oncology, 2001. ZumbergMS , delRoarioML , NejameCF , PollockBH , GarzarellaL , KaoKJ , et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/µL versus 20,000/µL trigger. Biology of Blood and Marrow Transplantation2002;8:569‐76. ">Zumberg 2002</a>). </p> <p>The three included RCTs were distributed across the review's four subcategories as follows: </p> <p> <ul id="CD010983-list-0011"> <li> <p>No studies compared a lower platelet count threshold (5 x 10<sup>9</sup>/L) versus a standard platelet transfusion threshold (10 x 10<sup>9</sup>/L). </p> </li> <li> <p>All three studies compared a standard platelet transfusion threshold (10 x 10<sup>9</sup>/L) versus a higher platelet count threshold (20 x 10<sup>9</sup>/L, 30 x 10<sup>9</sup>/L, or 50 x 10<sup>9</sup>/L). </p> </li> <li> <p>No studies compared different platelet count thresholds (5 x 10<sup>9</sup>/L, 20 x 10<sup>9</sup>/L, 30 x 10<sup>9</sup>/L, or 50 x 10<sup>9</sup>/L) that did not include a comparison against the standard platelet transfusion threshold (10 x 10<sup>9</sup>/L). </p> </li> <li> <p>No studies compared alternative thresholds to guide prophylactic platelet transfusions (e.g. platelet mass, immature platelet fraction, absolute immature platelet number). </p> </li> </ul> </p> <p>This review therefore only discussed the subcategory that compared a standard platelet transfusion threshold (10 x 10<sup>9</sup>/L) versus a higher platelet count threshold (20 x 10<sup>9</sup>/L, 30 x 10<sup>9</sup>/L, or 50 x 10<sup>9</sup>/L). </p> <p>See <a href="#CD010983-tbl-0002">Table 1</a> for study characteristics including: number and type of participants; type of intervention (actual thresholds used); duration of study; dose of platelet component; type of platelet product; and primary outcome. </p> <div class="table" id="CD010983-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of the included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Platelet component dose</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of platelet component</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcome</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. "><b>Diedrich 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages undergoing<br/> an allogeneic HSCT </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic plt transfusion if plt count &lt; 10 x 10<sup>9</sup>/L<br/> versus<br/> prophylactic plt transfusion if plt count &lt; 30 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average yield (mean ± SD)</p> <p>4.10 x 10<sup>11</sup> ± 0.2 x 10<sup>11</sup> (buffy coat) </p> <p>3.80 x 10<sup>11</sup> ± 0.2 x 10<sup>11</sup> (apheresis) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum duration of observation was 37 days (7 days pre‐HSCT and 30 days post‐HSCT). No information available on the number of participants who died or were lost to follow‐up </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leucodepleted, ABO ‐matched, irradiated<br/> pooled random‐donor platelets (buffy coat) 85%<br/> Apheresis 15% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of platelet transfusions</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. "><b>Heckman 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults with acute leukaemia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic plt transfusion if plt count ≤ 10 x 10<sup>9</sup>/L </p> <p>versus</p> <p>prophylactic plt transfusion if plt count ≤ 20 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 apheresis unit.</p> <p>Average yield each study year (number of transfusions)</p> <p>4.9 x 10<sup>11</sup> 1991 (n = 502) </p> <p>4.5 x10<sup>11</sup> 1992 (n = 418) </p> <p>4.7 x 10<sup>11</sup> 1993 (n = 399) </p> <p>4.0 x 10<sup>11</sup> 1994 (n = 400) </p> <p>4.3 x 10<sup>11</sup> 1995 (n = 398) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 24 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leucodepleted</p> <p>Apheresis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. "><b>Rebulla 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adolescents and adults with AML</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic plt transfusion if plt count &lt; 10 x 10<sup>9</sup>/L </p> <p>versus</p> <p>prophylactic plt transfusion if plt count &lt; 20 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> <p>2.2 x 10<sup>11</sup> (pooled) </p> <p>2.8 x 10<sup>11</sup> (apheresis) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 27.8 to 29.7 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apheresis and pooled products</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency and severity of haemorrhage</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AML = acute myeloid leukaemia</p> <p>HSCT = haematopoietic stem cell transplant</p> <p>plt = platelet</p> <p>SD = standard deviation</p> </div> </div> <section id="CD010983-sec-0065"> <h6 class="title">Study design</h6> <p>All three studies were open‐label studies. Two studies were single‐centre parallel RCTs (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>), and one study was a multicentre parallel RCT (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). </p> </section> <section id="CD010983-sec-0066"> <h6 class="title">Study size</h6> <p>The number of participants randomised ranged from 78 in <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a> to 276 in <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>. </p> </section> <section id="CD010983-sec-0067"> <h6 class="title">Setting</h6> <p>Two studies were conducted in the 1990s (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>), and one study was conducted in the early 2000s (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>). The studies were conducted in Italy (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>), Sweden (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>), and the United States (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>). </p> </section> <section id="CD010983-sec-0068"> <h6 class="title">Participants</h6> <p>In total, 520 participants were randomised; of these, 499 were included in the analysis. We excluded 21 participants randomised in <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a> from the analysis (16 no study records received; two received non‐myeloablative chemotherapy; three died (two within 24 hours of enrolment in the study). Two of the studies examined adults with acute leukaemia; one included adults with acute lymphocytic leukaemia (ALL) or acute myeloid leukaemia (AML) (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>), and the other included only adults with AML (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). Both studies excluded adults with acute promyelocytic leukaemia (APL). The third study included both adults and children undergoing an allogeneic HSCT (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>). </p> </section> <section id="CD010983-sec-0069"> <h6 class="title">Intervention</h6> <p>Two studies compared a prophylactic transfusion threshold of 10 x 10<sup>9</sup>/L with a threshold of 20 x 10<sup>9</sup>/L (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). One study compared a threshold of 10 x 10<sup>9</sup>/L with a threshold of 30 x 10<sup>9</sup>/L (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>). </p> </section> <section id="CD010983-sec-0070"> <h6 class="title">Co‐interventions</h6> <p>In two of the three studies a red cell transfusion policy was stated (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). Both studies transfused red cells when the haemoglobin was less than 80 g/L. </p> </section> <section id="CD010983-sec-0071"> <h6 class="title">Outcomes</h6> <p>Two of the three studies defined a primary outcome (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). In <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>, the primary outcome was the frequency and severity of bleeding, and the secondary outcome was the number of platelet transfusions, whereas in <a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>, the number of platelet transfusions was the primary outcome, with bleeding as one of the secondary outcomes. The third study, <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>, stated that its main aims were to look at platelet use and bleeding complications. All three studies commented on adverse events associated with platelet transfusions. </p> </section> <section id="CD010983-sec-0072"> <h6 class="title">Funding sources</h6> <p>Two studies reported the funding sources for the trial (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>). All funding sources were either charitable foundations or government funds. </p> </section> </section> </section> <section id="CD010983-sec-0073"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD010983-sec-0151" title="">Characteristics of excluded studies</a> for further details. </p> <p> <ul id="CD010983-list-0012"> <li> <p>Twelve studies were excluded because they compared different participant groups (<a href="./references#CD010983-bbs2-0009" title="AndrewM , VeghP , CacoC , KirpalaniH , JefferiesA , OhlssonA , et al. A randomized controlled trial of platelet transfusions in thrombocytopenic premature infants. Journal of Pediatrics1993;123(2):285‐91. ">Andrew 1993</a>; <a href="./references#CD010983-bbs2-0011" title="ArnoldDM , CrowtherMA , CookRJ , SigouinC , HeddleNM , MolnarL , et al. Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses. Transfusion2006;46(8):1286‐91. ">Arnold 2006</a>; <a href="./references#CD010983-bbs2-0013" title="BaiCM , XuGX , ZhaoYQ , HanSM , ShanYD . A multi‐centre clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy‐induced thrombocytopenia in patients with solid tumor. Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae2004;26(4):437‐41. ">Bai 2004</a>; <a href="./references#CD010983-bbs2-0039" title="FanningJ , HilgersRD , MurrayKP , BoltK , AughenbaughDM . Conservative management of chemotherapy‐induced thrombocytopenia in women with gynecological cancers. Gynecologic Oncology1995;59:191‐3. ">Fanning 1995</a>; <a href="./references#CD010983-bbs2-0042" title="GajicO , DzikWH , ToyP . Fresh frozen plasma and platelet transfusion for non‐bleeding patients in the intensive care unit: Benefit or harm?. Critical Care Medicine2006;35(5 Suppl):S170‐3. ">Gajic 2006</a>; <a href="./references#CD010983-bbs2-0043" title="GerdayE , BaerVL , LambertDK , PauDA , Sola‐VisnerMC , PysherTJ , et al. Testing platelet mass versus platelet count to guide platelet transfusions in the neonatal intensive care unit. Transfusion2009;49:2034‐9. ">Gerday 2009</a>; <a href="./references#CD010983-bbs2-0070" title="JohanssonPI , StensballeJ , RosenbergI , HisløvTL , JørgensenL , SecherNH . Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion2007;47(4):593‐8. ">Johansson 2007</a>; <a href="./references#CD010983-bbs2-0071" title="JulmyF , AmmannRA , TaleghaniBM , FontanaS , HirtA , LeibundgutK . Transfusion efficacy of ABO major‐mismatched platelets (PLTS) in children is inferior to that of ABO‐identical platelets. Transfusion2009;91(1):21‐33. ">Julmy 2009</a>; <a href="./references#CD010983-bbs2-0094" title="NCT00699621 . Platelet transfusion in acute intracerebral haemorrhage. https://clinicaltrials.gov/ct2/show/NCT00699621 (accessed 14 April 2010). ">NCT00699621</a>; <a href="./references#CD010983-bbs2-0111" title="ReedRL , CiavarellaD , HeimbachDM , BaronL , PavlinE , CountsRB , et al. Prophylactic platelet administration during massive transfusion. A prospective, randomized, double‐blind clinical study. Annals of Surgery1986;203(1):40‐8. ">Reed 1986</a>; <a href="./references#CD010983-bbs2-0134" title="SpiessBD , RoystonD , LevyJH , FitchJ , DietrichW , BodyS , et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion2004;44(8):1143‐8. ">Spiess 2004</a>; <a href="./references#CD010983-bbs2-0145" title="Vadhan‐RajS , KavanaghJJ , FreedmanRS , FolloderJ , CurrieLM , Bueso‐RamosC , et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy‐associated severe thrombocytopenia: a randomised cross‐over study. The Lancet2002;359:2145‐52. ">Vadhan‐Raj 2002</a>). </p> </li> <li> <p>Seventy‐three studies compared different types of platelet formulations with outcome measures not relevant to the eligibility criteria (<a href="./references#CD010983-bbs2-0005" title="AgliastroRE , DeFrancisciG , BonaccorsoR , SpicolaD , ZiinoO , AricoM , et al. Clinical study in pediatric hemato‐oncology patients: efficacy of pathogen inactivated platelets versus apheresis platelets. Transfusion2006;46(9S):117A. ">Agliastro 2006</a>; <a href="./references#CD010983-bbs2-0006" title="AkkökCA , BrinchL , LauritzsenGF , SolheimBG , Kjelsden‐KraghJ . Clinical effect of buffy‐coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy. Vox Sanguinis2007;93(1):42‐8. ">Akkök 2007</a>; <a href="./references#CD010983-bbs2-0007" title="AndersonNA , GrayS , CopplestoneJA , ChanDC , HamonM , PrenticeAG , et al. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfusion Medicine1997;7:33‐9. ">Anderson 1997</a>; <a href="./references#CD010983-bbs2-0010" title="ArnoldDM , HeddleNM , CarruthersJ , KulczyckyM , SigouinC , BlajchmanMA . A randomized crossover trial comparing in‐vivo platelet recovery and survival of leukoreduced apheresis and whole blood derived platelets. Transfusion2004;44(supplement):1A. ">Arnold 2004</a>; <a href="./references#CD010983-bbs2-0015" title="BentleyM , TaylorK , KellyC , TaylorD , LeachB , RodwellR , et al. Thrombopoietin derived autologous cryopreserved platelet support for peripheral blood progenitor cell transplantation. Haematology Society of Australia and New Zealand Annual Scientific Meeting. Perth, July 23‐26 2000. ">Bentley 2000</a>; <a href="./references#CD010983-bbs2-0017" title="BlumbergN , HealJM , RoweJM . Platelet transfusion and clinical outcome in acute leukemia in adults. Transfusion2002;42(9S):5S. ">Blumberg 2002</a>; <a href="./references#CD010983-bbs2-0018" title="BlumbergN , HealJM , RoweJM . A randomized trial of washed red blood cell and platelet transfusions in adult acute leukemia [ISRCTN76536440]. BMC Blood Disorders2004; Vol. 4, issue 6. [DOI: 10.1186/1471‐2326‐4‐6] ">Blumberg 2004</a>; <a href="./references#CD010983-bbs2-0019" title="BlundellEL , PamphilonDH , FraserID , KagenL , MenitoveJE , AsterRH , et al. A prospective randomised study of platelet concentrates irradiated with ultraviolet (UV)‐B light in patients with high grade haematological malignancy. Blood1992;80(10):215A. BlundellEL , PamphilonDH , FraserID , MenitoveJE , GreeenwaltTJ , SnyderEL , et al. A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet‐B light in patients with hematologic malignancy. Transfusion1996;36(4):296‐302. ">Blundell 1996</a>; <a href="./references#CD010983-bbs2-0023" title="CarrR , HuttonJL , JenkinsJA , LucasGF , AmphlettNW . Transfusion of ABO‐mismatched platelets leads to early platelet refractoriness. British Journal of Haematology1990;75:408‐13. ">Carr 1990</a>; <a href="./references#CD010983-bbs2-0028" title="CorashL , KlueterH , RhenenD , GulliksonH , PamphilonD , CazenaveJP , et al. Intercept platelet concentrates (IPC) are effective and safe for support of multiple cycles of thrombocytopenia: the eurosprite phase III trial. Hematology Journal2001;2(Supplement 1):178‐9. ">Corash 2001</a>; <a href="./references#CD010983-bbs2-0029" title="CoubanS , CarruthersJ , AndreouP , KlamaLN , BarrR , KeltonJG , et al. Platelet transfusions in children: results of a randomised prospective cross‐over trial of plasma removal and a prospective audit of WBC reduction. Transfusion2002;42:753‐8. ">Couban 2002</a>; <a href="./references#CD010983-bbs2-0031" title="DeWildt‐EggenJ , NautaS , SchrijverJG , vanMarwijkKM , BinsM , vanProoijenHC , et al. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion2000;40(4):398‐403. ">de Wildt‐Eggen 2000</a>; <a href="./references#CD010983-bbs2-0032" title="DiedrichB , RingdenO , WatzE , ShanwellA . A randomised study of buffy coat platelets in platelet additive solution 1‐5 versus 6‐7 days prior to prophylactic transfusion of allogeneic haematopoietic cell transplant recipients. Vox Sanguinis2009;97(3):254‐9. DiedrichB , WatzE , RingdenO , ShanwellA . A randomized study in allogeneic haematopoietic stem cell transplant recipients comparing prophylactic transfusion of buffy coat platelets stored for 1‐5 vs. 6‐7 days. Vox Sanguinis2008;95(Supp 1):Abstract. ">Diedrich 2009</a>; <a href="./references#CD010983-bbs2-0033" title="DiPietroG , MenicucciA , VenturiniS , GrazianiG , SaniR , AvanziG . Platelet transfusion support during bone marrow transplantation. Comparative study between the use of HLA platelet apheresis and random platelet apheresis. Trasfusione del Sangue1998;43(1):47‐50. ">Di Pietro 1998</a>; <a href="./references#CD010983-bbs2-0034" title="DumontLJ , DumontDF , UngerZM , SiegelA , SzczepiorkowskiZM , CorsonJS , et al. A randomized controlled trial comparing autologous radiolabeled in vivo platelet(plt) recoveries and survivals of 7‐day‐stored plt‐rich plasma and buffy coat plts from the same subjects. Transfusion 51;6:1241‐8. ">Dumont 2011</a>; <a href="./references#CD010983-bbs2-0045" title="GmürJ , vonFeltenA , OsterwalderB , HoneggerH , HermannA , SauterC , et al. Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia. Blood1983;62(2):473‐9. ">Gmür 1983</a>; <a href="./references#CD010983-bbs2-0047" title="GoodnoughLT , KuterDJ , McCulloughJ , SlichterSJ , DiPersioJ , RomoJ , et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood2001;98(5):1346‐51. ">Goodnough 2001</a>; <a href="./references#CD010983-bbs2-0050" title="GoodrichR , FolluaG , RobertsT . Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion2008;48(S2):20A. ">Goodrich 2008</a>; <a href="./references#CD010983-bbs2-0052" title="GrossmanL , MangalA , HislopTG , BuskardNA . Preliminary report on a randomized study of prophylactic (P) vs. therapeutic (T) platelet transfusions. Blood1980;80:271. ">Grossman 1980</a>; <a href="./references#CD010983-bbs2-0053" title="GurkanE , PatahPA , SalibaRM , RamosCA , AndersonBS , ChamplinR , et al. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation2007;40(5):461‐4. ">Gurkan 2007</a>; <a href="./references#CD010983-bbs2-0055" title="HarrupRA , KennedyJT , KissJ , DanielsB . Randomised blinded comparison of buffy coat plasma or T‐sol supported platelet transfusions. Haematology Society of Australia and New Zealand Annual Scientific Meeting. Hobart; Tasmania, October 1999. ">Harrup 1999</a>; <a href="./references#CD010983-bbs2-0056" title="HealJ , KemmotsuN , RoweJ , BlumbergN . A survival advantage in leukaemics receiving ABO identical platelets. Blood1991;78:349a. HealJ , RoweJ , BlumbergN . The importance of ABO identical platelet transfusions. Blood1991;78:348a. HealJ , RoweJ , McMicanA , FinkeK , BlumbergN . A randomised trial of ABO identical versus ABO unmatched platelet transfusions. Blood1989;74(7 Supp 1):215a. HealJM , RoweJM , McMicanA , MaselD , FinkeC , BlumbergN . The role of ABO matching in platelet transfusion. European Journal of Haematology1993;50:110‐7. ">Heal 1993</a>; <a href="./references#CD010983-bbs2-0058" title="HeddleNM , KlamaL , SingerJ , RichardsC , FedakP , WalkerI , et al. The role of the plasma from platelet concentrates in transfusion reactions. The New England Journal of Medicine1994;331(10):625‐8. ">Heddle 1994</a>; <a href="./references#CD010983-bbs2-0059" title="HeddleNM , KlamaL , MeyerR , WalkerI , BoshkovL , RobertsR , et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion1999;39(3):231‐8. ">Heddle 1999</a>; <a href="./references#CD010983-bbs2-0060" title="HeddleNM , BlajchmanMA , MeyerRM , LiptonJH , WalkerIR , SherGD , et al. A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets. Transfusion2002;42(5):556‐66. ">Heddle 2002</a>; <a href="./references#CD010983-bbs2-0062" title="HeddleNM , CookRJ , BlajchmanMA , BartyRL , SigouinCS , BoyeDM , et al. Assessing the effectiveness of whole blood‐derived platelets stored as a pool: a randomized block noninferiority trial. Transfusion2005;45(6):896‐903. ">Heddle 2005</a>; <a href="./references#CD010983-bbs2-0064" title="HeddleNM , CookRJ , TinmouthA , KouroukisCT , HervigT , KlapperE , et al. A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood2009;113(7):1564‐73. HeddleNM , WuC , VassalloR , CareyP , ArnoldD , LozanoM , et al. Adjudicating bleeding events in a platelet dose study: impact on outcome results and challenges. Transfusion2011;51:2304‐10. NCT00420914 . Strategies for Transfusion of Platelets (SToP). http://clinicaltrials.gov/show/NCT00420914 (accessed 15 September 2009). ">Heddle 2009</a>; <a href="./references#CD010983-bbs2-0065" title="HigbyDJ , CohenE , HollandJF , SinksL . The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion1974;14:440‐5. ">Higby 1974</a>; <a href="./references#CD010983-bbs2-0066" title="ISRCTN01292427 . Comparison of in vivo outcome following transfusion of dynamic light scattering‐screened versus unscreened platelets in hematologic malignancy. www.controlled‐trials.com/ISRCTN01292427 (accessed 16 June 2014). ">ISRCTN01292427</a>; <a href="./references#CD010983-bbs2-0067" title="ISRCTN49080246 . Platelet Process Improvement Project. http://www.controlled‐trials.com/ISRCTN49080246 (accessed 16 June 2011). ">ISRCTN49080246</a>; <a href="./references#CD010983-bbs2-0068" title="ISRCTN56366401 . Platelet responsiveness and outcome from platelet transfusion ‐ does inherent variation in donor platelet function affect the clinical efficacy of apheresis platelets? A randomised double blind single centre trial. UK Clinical Research Network (UKCRN) http://www.controlled‐trials.com/ISRCTN56366401 (accessed 16 June 2014). ">ISRCTN56366401</a>; <a href="./references#CD010983-bbs2-0072" title="KakaiyaRM , HezzeyAJ , BoveJR , KatzAJ , GencoPV , BuchholzDH , et al. Alloimmunization following apheresis platelets vs. pooled platelet concentrates. A prospective randomized study. Transfusion1981;21(5):600. ">Kakaiya 1981</a>; <a href="./references#CD010983-bbs2-0073" title="KerkhoffsJH , NovotnyVM , TeBoekhorstPA , SchipperusMR , ZwagingaJJ , vanPampusI , et al. Clinical effectiveness and safety of pooled, random donor platelet concentrates, leucoreduced and stored up to seven days in either plasma or additive solution with and without pathogen reduction in hemato‐oncological patients. Transfusion2009;49(s3):2A. KerkhoffsJLH , vanPuttenWL , NovotnyVM , TeBoekhorstPA , SchipperusMR , ZwagingaJJ , et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. British Journal of Haematology2010;150(2):209‐17. ">Kerkhoffs 2010</a>; <a href="./references#CD010983-bbs2-0074" title="AckermanSJ , KlumppTR , GuzmanGI , HermanJH , GaughanJP , BleeckerGC , et al. Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double‐blind trial. Transfusion2000;40(12):1457‐62. HermannJH , KlumppTR , ChristmanRA , RussoRR , GoldbergSL , ManganKF . The effect of platelet dose on the outcome of prophylactic platelet transfusion. Transfusion1995;35(10s):46S. KlumppT , HermanJH , ChristmanRA , RussoRR , GoldbergSL , MacDonaldJS , et al. The effect of platelet dose on the interval between platelet transfusions in patients undergoing bone marrow or peripheral blood stem cell transplantation. Proceedings of American Society of Clinical Oncology (ASCO). 1995:536. KlumppTR , HermanJH , GaughanJP , RussoRR , ChristmanRA , GoldbergSL , et al. Clinical consequences of alterations in platelet dose: a prospective, randomized, double‐blind trial. Transfusion1999;39:674‐81. ">Klumpp 1999</a>; <a href="./references#CD010983-bbs2-0075" title="KluterH , DorgesL , MaassE , WagnerT , BartelsH , KirchnerH . In‐vivo evaluation of random donor platelet concentrates from pooled buffy coats. Annals of Hematology1996;73(2):85‐9. ">Kluter 1996</a>; <a href="./references#CD010983-bbs2-0076" title="LapierreV , BenhamouE , TramalloniD , BraultP , Valteau‐CouanetD , DucourtieuxM , et al. A randomised trial of platelet transfusion policies after blood stem cell transplantation in young children: reduction of number of single platelet concentrate donors per child. Bone Marrow Transplantation2003;31(Supplement 1):P756. ">Lapierre 2003</a>; <a href="./references#CD010983-bbs2-0078" title="LeachMF , FairweatherRB , AubuchonJP . Use of warmed single donor platelets in autologous bone marrow transplant patients. Transfusion1991;31(Suppl):20S. ">Leach 1991</a>; <a href="./references#CD010983-bbs2-0079" title="LeeEJ , SchifferCA . ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion1989;29(5):384‐9. ">Lee 1989</a>; <a href="./references#CD010983-bbs2-0083" title="LozanoM , KnutsonF , TardivelR , CidJ , MaymóR , LöfH , et al. Frequency of prophylactic transfusion failure: a novel outcome to evaluate platelet components stored more than 5 days. Transfusion2010;50(Supp 2):25A‐6A. ">Lozano 2010</a>; <a href="./references#CD010983-bbs2-0084" title="LozanoM , KnutsonF , TardivelR , CidJ , MaymóRM , LöfH , et al. A multi‐centre study of therapeutic efficacy and safety of platelet components treated with amotsalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. British Journal of Haematology2011;153(3):393‐401. ">Lozano 2011</a>; <a href="./references#CD010983-bbs2-0085" title="LuFQ , AnWX , KangW , ZhangYL . Effect of reducing prophylactic platelet transfusion dose on bleeding in thrombocytopenia patients [降低预防性血小板输注剂量对慢性血小板减少症患者出血风险的影响]. International Journal of Blood Transfusion and Hematology2011;34(4):295‐8. LuFQ , WangWM , YuM . Effect of reducing prophylactic platelet transfusion dose on bleeding in thrombocytopenic patients. Vox Sanguinis2011;101(S1):310 (P‐577). ">Lu 2011</a>; <a href="./references#CD010983-bbs2-0087" title="BenjaminRJ , GoodnoughLT , Lopez‐PerezI , StraussR , McCulloughJ , SlichterS , et al. Fresh (1‐2 day‐old) vs. aged (4‐5 day‐old) INTERCEPT platelets and conventional platelets provide comparable count increments. However fresh platelets result in superior hemostasis: results of the SPRINT trial. Transfusion2003;43(9S):9A. CorashL , LinJS , ShermanCD , EidenJ . Determination of acute lung injury following repeated platelet transfusions. Blood2010; Vol. 117, issue 3:1014‐20. [PUBMED: 20935256] GoodnoughLT , McCulloughJ , SlichterS , StraussR , LinJ , ConlanM . A platelet transfusion threshold of 20 x 109/L compared to 10 x 109/L is associated with increased pre‐transfusion bleeding and increased platelet transfusions: results of the SPRINT study. Transfusion2002;42(9S):17S. KluterH , ChapuisB , CazenaveJ , HastkaJ , BerisP , DufourP , et al. Apheresis platelets treated with the INTERCEPT Blood System for pathogen inactivation provide platelet count increments and hemostasis comparable to conventional platelets. Vox Sanguinis2002;83(Suppl 1):110a. McCulloughJ , VesoleDH , BenjaminRJ , SlichterSJ , PinedaA , SynderE , et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood2004;104(5):1534‐41. MurphyS , SlichterS , McCulloughJ , StraussR , WoodL , LinJ , et al. INTERCEPT platelets are hemostatically as effective as conventional platelet in the prophylaxis and treatment of bleeding: results of the SPRINT trial. Vox Sanguinis2002;83(109):Abstract. MurphyS , SynderE , CableR , SlichterSJ , StraussRG , McCulloughJ , et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion2006;46(1):24‐33. PinedaA , McCulloughJ , BenjaminRJ , CableR , StraussRG , BurgstalerE , et al. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial. Transfusion2006;46(4):562‐71. [PUBMED: 16584432] SlichterSJ , MurphyS , BuchholzD , LinJ , CorashL , ConlanM . INTERCEPT platelets (plts) and conventional plts provide comparable hemostatic response in thrombocytopenic patients: the SPRINT trial. Blood2002;11(Pt 2):141b. SnyderE , McCulloughJ , SlichterSJ , StraussRG , Lopez‐PlazaI , LinJS , et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion2005; Vol. 45, issue 12:1864‐75. [PUBMED: 16371039] StraussRG , SlichterS , Lopez‐PlazaI , GoodnoughLT , McCulloughJ , LinJ , et al. Intercept platelets exhibit immunological refractoriness comparable to conventional platelets. Haematologica2004;89(Suppl 1):Abstract. VesoleD , StadtmauerE , GoodnoughLT , CoutreS , HowardF , LinJS , et al. Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation (SCT): results of the Phase III SPRINT trial of INTERCEPT pathogen inactivated platelets. Biology of Blood and Bone Marrow Transplantation2004; Vol. 10, issue 2:233. ">McCullough 2004</a>; <a href="./references#CD010983-bbs2-0089" title="MesserschmidtGL , MakuchR , AppelbaumF , UngerleiderRS , AbramsR , O'DonnellJ , et al. A prospective randomized trial of HLA‐matched versus mismatched single‐donor platelet transfusions in cancer patients. Cancer1988;62(4):795‐801. ">Messerschmidt 1988</a>; <a href="./references#CD010983-bbs2-0090" title="AmbrusoDR , ThurmanG , MarschnerS , GoodrichRP . Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light‐treated platelet concentrates. Transfusion2009;49(12):2631‐6. [PUBMED: 19694996] GoodrichR , RobertsT , FolleaG . Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion2008;48(Suppl):20A. Abstract No. S49‐020G. The Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion2010;50:2362‐75. ">Mirasol 2010</a>; <a href="./references#CD010983-bbs2-0091" title="MurphyS , LitwinS , HerringLM , KochP , RemischovkyJ , DonaldsonMH , et al. Indications for platelet transfusion in children with acute leukemia. American Journal of Hematology1982;12:347‐56. ">Murphy 1982</a>; <a href="./references#CD010983-bbs2-0092" title="MurphyMF , MetcalfeP , ThomasH , EveJ , OrdJ , ListerTA , et al. Use of leucocyte‐poor blood components and HLA‐matched‐platelet donors to prevent HLA alloimmunization. British Journal of Haematology1986;62:529‐34. ">Murphy 1986</a>; <a href="./references#CD010983-bbs2-0095" title="NCT01615146 . Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot. http://ClinicalTrials.gov/show/NCT01615146     (accessed 16 April 2013). ">NCT01615146</a>; <a href="./references#CD010983-bbs2-0098" title="NorvilleR , HindsP , WilimasJ , FaircloughD , FischlS , KunkelK . The effects of infusion methods on platelet count, morphology, and corrected count increment in children with cancer: in vitro and in vivo studies. Oncology Nursing Forum1994;21(10):1669‐73. ">Norville 1994</a>; <a href="./references#CD010983-bbs2-0099" title="NorvilleR , HindsP , WilimasJ , FischlS , KunkelK , FaircloughD . The effects of infusion rate on platelet outcomes and patient responses in children with cancer: an in vitro and in vivo study. Oncology Nursing Forum1997;24(10):1789‐93. ">Norville 1997</a>; <a href="./references#CD010983-bbs2-0100" title="OksanenK , KekomakiR , RuutuT , KoskimiesS , MyllylaG . Prevention of alloimmunization in patients with acute leukemia by use of white cell‐reduced blood components: A randomized trial. Transfusion1991;31:588‐94. ">Oksanen 1991</a>; <a href="./references#CD010983-bbs2-0101" title="OksanenK , EbelingF , KekomäkiR , ElonenE , SahlstedtL , VolinL , et al. Adverse reactions to platelet transfusions are reduced by use of platelet concentrates derived from buffy coat. Vox Sanguinis1994;67(4):356‐61. ">Oksanen 1994</a>; <a href="./references#CD010983-bbs2-0103" title="PamphilonDH . Comparative clinical studies of platelet concentrates: Effects on clinical outcome and the use of healthcare resources. Transfusion Science1996;17(3):343‐6. ">Pamphilon 1996</a>; <a href="./references#CD010983-bbs2-0117" title="SchifferCA , DutcherJP , AisnerJ , HoggeD , WiernikPH , ReillyJP , et al. A randomized trial of leukocyte‐depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood1983;62:815‐20. ">Schiffer 1983</a>; <a href="./references#CD010983-bbs2-0119" title="ShanwellA , LarssonS , AschanJ , RingdenO . A randomized trial comparing the use of fresh and stored platelets in the treatment of bone marrow transplant recipients. European Journal of Haematology1992;49(2):77‐81. ">Shanwell 1992</a>; <a href="./references#CD010983-bbs2-0122" title="SingerJ , AliAM , WarkentinTE , BlajchmanMA , KeltonJG . A prospective randomized study of platelet support in leukemic patients. Transfusion1988;72(5 Supp):285A. ">Singer 1988</a>; <a href="./references#CD010983-bbs2-0123" title="SintnicolaasK , VriesendorpHM , SizooW , Stenfert KroeseWF , HaijeWG , HopWC , et al. Delayed alloimmunisation by random single donor platelet transfusions. A randomised study to compare single donor and multiple donor platelet transfusions in cancer patients with severe thrombocytopenia. The Lancet1981;1(8223):750‐4. ">Sintnicolaas 1981</a>; <a href="./references#CD010983-bbs2-0124" title="SintnicolaasK , VeldenK , SizooW , HaijeWG , AbelsJ , LowenbergB . Comparison of prophylactic and therapeutic single‐donor platelet transfusions in patients with acute leukaemia. British Journal of Haematology1982;50:684. ">Sintnicolaas 1982</a>; <a href="./references#CD010983-bbs2-0125" title="SintnicolaasK , vanMarwijk KooijM , vanProoijenHC , vanDijkBA , vanPuttenWL , ClaasFH , et al. Leukocyte depletion of random single‐donor platelet transfusions does not prevent secondary human leukocyte antigen‐alloimmunization and refractoriness: A randomized prospective study. Blood1995;85:824‐8. ">Sintnicolaas 1995</a>; <a href="./references#CD010983-bbs2-0126" title="SlichterSJ , GrabowskiM , Townsend‐McCallD , BolgianoD . Prospective randomized transfusion trial to directly compare fresh and stored apheresis platelets (AP) and pooled random donor platelet concentrates (PC) in thrombocytopenic patients. Blood1998;92:Abstract. ">Slichter 1998</a>; <a href="./references#CD010983-bbs2-0128" title="SlichterSJ , RaifeTJ , DavisK , RheinschmidtM , BuchholzDH , CorashL , et al. Platelets photochemically treated with amotsalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion2006;46(5):731‐40. ">Slichter 2006</a>; <a href="./references#CD010983-bbs2-0130" title="AssmanS , TriulziDJ , McCulloughJ , HarrisonRW , SlichterSJ . Cost tradeoffs of low‐, medium‐, and high‐dose platelet transfusions. Transfusion2013;53(Supplement):188A. JosephsonC , SloanS , GrangerS , CastillejoM , StraussRG , SlichterS , et al. Increased incidence of Grade 2 and higher bleeding in pediatric PLADO trial patients. Transfusion2009;49(S3):19A‐20A. JosephsonCD , GrangerS , AssmannSF , CastillejoM‐I , StraussRG , SlichterSJ , et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment‐induced hypoproliferative thrombocytopenia. Blood2012;120(4):748‐60. KaufmanRM , AssmannSF , TriulziDJ , StraussRG , NessP , GrangerS , et al. Transfusion‐related adverse events in the platelet dose study. Transfusion2015;55(1):144‐53. NCT00128713 . Optimal platelet dose strategy for management of thrombocytopenia. http://clinicaltrials.gov/show/NCT00128713 (accessed 16 April 2010). SlichterSJ . Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. Journal of Clinical Apheresis2006;21:78‐84. SlichterSJ , KaufmanRM , AssmanSF , BrecherME , GernsheimerT , HillyerCD , et al. Effects of prophylactic platelet (Plt) dose on transfusion (Tx) outcomes (PLADO trial). [50th Annual Meeting of the American Society of Hematology]. Blood2008;112(11):Abstract 285. SlichterSJ , KaufmanRM , AssmannSF , McCulloughJ , TriulziDJ , StraussRG , et al. Dose of prophylactic platelet transfusions and prevention of haemorrhage. The New England Journal of Medicine2010;362:600‐13. TriulziDJ , AssmannSF , StraussRG , NessPM , HessJ , GrangerS , et al. The effect of platelet characteristics on the platelet increment and HLA alloimmunization in hypoproliferative thrombocytopenia. Transfusion2010;50(Supplement):3A. TriulziDJ , AssmannSF , StraussRG , NessPM , HessJR , KaufmanRM , et al. The impact of platelet transfusion characteristics on post‐transfusion platelet increments and clinical bleeding in patients with hypo‐proliferative thrombocytopenia. Blood2012;119(23):5553‐62. ">Slichter 2010</a>; <a href="./references#CD010983-bbs2-0132" title="SolomonJ , BofenkampT , FaheyJL , ChillarRK , BeutlerE . Platelet prophylaxis in acute non‐lymphoblastic leukemia. The Lancet1978;1 (8058):267. ">Solomon 1978</a>; <a href="./references#CD010983-bbs2-0135" title="CampbellHE , EstcourtLJ , StokesEA , LlewelynCA , MurphyMF , WoodEM , et al. TOPPS Study Investigators. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion2014;54(10):2394‐403. ISRCTN08758735 . A randomised controlled trial of prophylactic versus no‐prophylactic platelet transfusions in patients with haematological malignancies. http://www.controlled‐trials.com/ISRCTN08758735 (accessed 6 February 2010). PowterG , DyerC , BielbyL . Objective assessment of bleeding in patients with haematological malignancies in an international study of platelet transfusions ‐ how was consistency achieved [31st Annual Scientific Meeting of the British Blood Transfusion Society, Birmingham]. Transfusion Medicine2013;23:46‐7. StanworthSJ , DyerC , ChooL , BakraniaL , CopplestoneA , LlewelynC , et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfusion Medicine Reviews2010;24(3):163‐71. StanworthSJ , EstcourtL , PowterG , KahanBC , DyerC , BakraniaL , et al. The effect of a no‐prophylactic versus prophylactic platelet transfusion strategy on bleeding in patients with hematological malignancies and severe thrombocytopenia (TOPPS trial). A randomized controlled, non‐inferiority trial. Blood2012;120(Supplement 1):Abstract 1. StanworthSJ , EstcourtLJ , LlewelynCA , MurphyMF , WoodEM , TOPPS Study Investigators. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion2014;54(10):2385‐93. StanworthSJ , EstcourtLJ , PowterG , KahanB , DyerC , ChooL , et al. A no‐prophylaxis platelet transfusion strategy for hematologic cancers. The New England Journal of Medicine2013;368(19):1771‐80. StanworthSJ , HudsonCL , EstcourtLJ , JohnsonRJ , WoodEM . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica2015;100(6):740‐7. WoodEM , HudsonC , EstcourtL , JohnsonR , StanworthSJ . Risk factors for bleeding: A modelling analysis of the TOPPS randomized controlled trial of prophylactic platelet transfusion. Blood2014;124(21):Abstract. ">Stanworth 2013</a>; <a href="./references#CD010983-bbs2-0139" title="StrindbergJ , BerlinG . Transfusion of platelet concentrates ‐ clinical evaluation of two preparations. European Journal of Haematology1996;57(4):307‐11. ">Strindberg 1996</a>; <a href="./references#CD010983-bbs2-0140" title="SweeneyJD , KouttabNM , PennCL , McHughKE , NelsonEJ , OblonDJ . A comparison of prestorage WBC‐reduced whole blood derived platelets in autologous progenitor cell transplant. Transfusion2000;40(7):794‐800. ">Sweeney 2000</a>; <a href="./references#CD010983-bbs2-0142" title="TinmouthA , KotchetkovaN , TomlinsonG , CrumpM , BrandweinJ , TannockI , et al. A randomised phase II trial of low dose and standard dose platelet transfusions during induction therapy for acute leukemia or autologous stem cell transplantation. Vox Sanguinis2002;83(Suppl 1):8. TinmouthA , TannockIF , CrumpM , TomlinsonG , BrandweinJ , MindenM , et al. Low‐dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor transplant and patients with acute leukaemia: a randomized controlled trial with a sequential Bayesian design. Transfusion Medicine2004;44:1711‐9. ">Tinmouth 2004</a>; <a href="./references#CD010983-bbs2-0144" title="EnrightH , DavisK , GernsheimerT , McCulloughJJ , WoodsonR , SlichterSJ . Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion2003;43(11):1545‐52. SlichterSJ , DavisK , EnrightH , BraineH , GernsheimerT , KaoKJ , et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood2005;105(10):4106‐14. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The New England Journal of Medicine1997;337:1861‐70. ">TRAP 1997</a>; <a href="./references#CD010983-bbs2-0146" title="VanMarwijkKM , vanProoijenHC , MoesM , Bosma‐stantsI , AkkermanJW . Use of leukocyte‐depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial. Blood1991;77:201‐5. ">Van Marwijk 1991</a>; <a href="./references#CD010983-bbs2-0147" title="CazenaveJP , DavisK , CorashL . Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx technology. Seminars in Hematology2001;38(4 Supp 11):46‐54. CazenaveJP , vanRhenenD , GullikssonH , PamphilonD , LjungmanP , DavisK , et al. INTERCEPT buffy coat platelets (IPC) are effective during multiple episodes of thrombocytopenia: the EUROSPRITE trial. Transfusion Clinique et Biologique2001;8(Supp 1):Various. LjungmanP , vanRhenenD , PamphilonD , MetzelP , MarblieS , LinJ , et al. Results of the EUROSPRITE phase III trial: INTERCEPT buffy coat platelet concentrates (IPC) provide effective hemostasis for thrombocytopenic (TCP) patients (PTS). Transfusion Clinique et Biologique2001;8(Supp 1):100s. PamphilonD , BuchholzDH , CazenaveJP , ConlanM , CorashL , DavisK , et al. The EUROSPRITE phase III trial of INTERCEPT buffy coat platelet concentrates (IPC) demonstrates IPC are safe when transfused to thrombocytopenic (TCP) patients (PTS). Transfusion Clinique et Biologique2001;8(Supp 1):100‐1s. vanRhenenD , GullikssonH , CazenaveJP , PamphilonD , LjungmanP , KluterH , et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood2003;101(6):2426‐33. ">van Rhenen 2003</a>; <a href="./references#CD010983-bbs2-0154" title="NCT00521664 . A trial comparing a prophylactic with a therapeutic platelet strategy in two groups. http://clinicaltrials.gov/show/NCT00521664 (accessed 4 January 2010). Schaefer‐EckartK , WendelinK , PilzB , KramerM , EhningerG , WilhelmM , et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood2014;124(21):Abstract. Schaefer‐EckartK , WendelinK , WilhelmM , MahlknechtU , ConradiR , SchaichM , et al. Interim analysis of a prospective randomised study comparing a therapeutic platelet strategy with the prophylactic platelet transfusion standard in patients after autologous peripheral stem cell transplantation (ASCT) [48th Annual Meeting of the American Society of Hematology]. Blood2006;108(11):Abstract. WandtH , Schaefer‐EckartK , PilzB , ThalheimerM , HoA , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in patients with acute myeloid leukemia. Final results of a randomized multicenter study comparing a prophylactic with a therapeutic transfusion strategy. Onkologie2010;33(6):Abstract. WandtH , Schaefer‐EckartK , PilzB , ThalheimerM , HoAD , SchaichM , et al. Experience with a therapeutic platelet transfusion strategy in acute myeloid leukaemia: Preliminary results of a randomised multicenter study after enrolment of 175 patients [51st ASH Meeting and Exposition]. Blood2009;11(Supplement):Abstract. WandtH , Schaefer‐EckartK , WendelinK , PilzB , WilhelmM , ThalheimerM , et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open‐label, multicentre, randomised study. The Lancet2012;380(9850):1309‐16. WandtH , Schäfer‐EckartK , WendelinK , RottmannM , ThalmeimerM , SchubertMS , et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: final analysis of a randomised study after high‐dose chemotherapy and PBSCT. Bone Marrow Transplantation2009;43 Supp 1:S23. WandtH , WendelinK , Schaefer‐EckartK , ThalheimerM , SchubertMS , ConradiR , et al. Therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts)2008;112:Abstract 286. ">Wandt 2012</a>; <a href="./references#CD010983-bbs2-0155" title="WangSE , LaraPN , LeeOA , ReedJ , WangLR , PalmerP , et al. Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double‐blind placebo‐controlled trial. American Journal of Hematology2002;70(3):191‐4. ">Wang 2002</a>; <a href="./references#CD010983-bbs2-0158" title="WilliamsonLM , WimperisJZ , WilliamsonP , CopplestoneJA , GooiHC , MorgensternGR , et al. Bedside filtration of blood products in the prevention of HLA alloimmunization: A prospective randomized study. Alloimmunization Study Group. Blood1994;83:3028‐35. ">Williamson 1994</a>; <a href="./references#CD010983-bbs2-0162" title="ZhaoSM , ChengXL , HuJ , XiangGC , ZhangJS , LiRQ . Clinical assessment of preventing febrile nonhemolytic transfusion reaction by leucocyte depleted blood transfusion. Zhongguo Shi Yan Xue Ye Xue Za Zhi2002;10(6):568‐70. ">Zhao 2002</a>). </p> </li> <li> <p>Three records were guidelines (<a href="./references#CD010983-bbs2-0040" title="FolleaG . Homologous platelet concentrates: products available and utilisation rules in oncology and haematology. Hematologie2004;10(3):233‐44. ">Follea 2004</a>; <a href="./references#CD010983-bbs2-0116" title="SamamaCM , DjoudiR , LecompteT , NathanDN , SchvedJF . Perioperative platelet transfusion: recommendations of the Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSaPS) 2003. Canadian Journal of Anaesthesia2005;52(1):30‐7. SamamaCM , DjoudiR , LecompteT , NathanN , SchvedJF . Perioperative platelet transfusion. Recommendations of the French Health Products Safety Agency (AFSSAPS) 2003. Minerva Anestesiologica2006;72(6):447‐52. ">Samama 2005</a>; <a href="./references#CD010983-bbs2-0143" title="TosettoA , BalduiniCL , CattaneoM , DeCandiaE , MarianiG , MolmanAC , et al. Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research2009;125(5):e13‐8. ">Tosetto 2009</a>). </p> </li> <li> <p>One record was an audit (<a href="./references#CD010983-bbs2-0106" title="QureshiH , LoweD , DobsonP , Grant‐CaseyJ , ParrisE , DaltonD , et al. National comparative audit of the use of platelet transfusions in the UK. Transfusion Clinique Et Biologique2007;14(6):509‐13. ">Qureshi 2007</a>). </p> </li> <li> <p>Thirty‐nine records were reviews (<a href="./references#CD010983-bbs2-0008" title="AndreuG , VasseJ , TardivelR , SemanaG . Platelet transfusion: products, indications, dose, threshold and efficacy. Transfusion Clinique Et Biologique2009;16(2):118‐33. ">Andreu 2009</a>; <a href="./references#CD010983-bbs2-0012" title="AvvisatiG , TirindelliMC , AnnibaliO . Thrombocytopenia and hemorrhagic risk in cancer patients. Critical Reviews in Oncology/Hematology2003;48(Suppl 1):S13‐6. ">Avvisati 2003</a>; <a href="./references#CD010983-bbs2-0014" title="BenjaminRJ , AndersonKC . What is the proper threshold for platelet transfusion in patients with chemotherapy‐induced thrombocytopenia?. Critical Reviews in Oncology/Hematology2002;42(2):163‐71. ">Benjamin 2002</a>; <a href="./references#CD010983-bbs2-0016" title="BlajchmanMA , SlichterSJ , HeddleNM , MurphyMF . New strategies for the optimal use of platelet transfusions. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program2008;2008:198‐204. ">Blajchman 2008</a>; <a href="./references#CD010983-bbs2-0020" title="BuhrkuhlDC . An update on platelet transfusion in hematooncology supportive care. Transfusion2010;50(10):2266‐76. ">Buhrkuhl 2010</a>; <a href="./references#CD010983-bbs2-0024" title="CasbardAC , WilliamsonLM , MurphyMF , RegeK , JohnsonT . The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A systematic review. Anaesthesia2004;59(6):550‐8. ">Casbard 2004</a>; <a href="./references#CD010983-bbs2-0027" title="CidJ , LozanoM . Lower or higher doses for prophylactic platelet transfusions: results of a meta‐analysis of randomized controlled trials. Transfusion2007;47:464‐70. ">Cid 2007</a>; <a href="./references#CD010983-bbs2-0035" title="DzikWH . Predicting hemorrhage using preoperative coagulation screening assays. Current Hematology Reports2004;3(5):324‐30. ">Dzik 2004</a>; <a href="./references#CD010983-bbs2-0048" title="GoodnoughLT , DiPersioJFD . Issues in the management of cancer‐related thrombocytopenia. Oncology2002;16(11):1558‐67. ">Goodnough 2002</a>; <a href="./references#CD010983-bbs2-0049" title="GoodnoughLT . Risks of blood transfusion. Anesthesiology Clinics of North America2005;23(2):241‐52. ">Goodnough 2005</a>; <a href="./references#CD010983-bbs2-0057" title="HealJM , BlumbergN . Optimizing platelet transfusion therapy. Blood Reviews2004;18(3):149‐65. ">Heal 2004</a>; <a href="./references#CD010983-bbs2-0061" title="HeddleNM , CookRJ , WebertKE , SigouinC , RebullaP . Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion2003;43:742‐52. ">Heddle 2003</a>; <a href="./references#CD010983-bbs2-0063" title="HeddleNM . Controversy concerning platelet dose. ISBT Science Series, Vol 2, No 1: State of the Art Presentations2007;2:220‐5. ">Heddle 2007</a>; <a href="./references#CD010983-bbs2-0069" title="JelicS , RadulovicS . Chemotherapy‐associated thrombocytopenia current and emerging management strategies. American Journal of Cancer2006;5(6):371‐82. ">Jelic 2006</a>; <a href="./references#CD010983-bbs2-0080" title="LeviMM , VinkR , deJongeE . Management of bleeding disorders by prohemostatic therapy. International Journal of Hematology2002;76(Suppl 2):139‐44. ">Levi 2002</a>; <a href="./references#CD010983-bbs2-0081" title="LordkipanidzeM , DiodatiJG , PharandC . Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence. Pharmacology &amp; Therapeutics2009;123(2):178‐86. ">Lordkipanidze 2009</a>; <a href="./references#CD010983-bbs2-0082" title="LozanoM , CidJ . The clinical implications of platelet transfusions associated with ABO or Rh[D) incompatibility. Transfusion Medicine Reviews2003;17(1):57‐68. ">Lozano 2003</a>; <a href="./references#CD010983-bbs2-0086" title="MartelN , WellsPS . A meta‐analysis to determine the risk of heparin induced thrombocytopenia (HIT) and isolated thrombocytopenia in prophylaxis studies comparing unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Blood2004;104(11):708a‐9a. ">Martel 2004</a>; <a href="./references#CD010983-bbs2-0088" title="McNicolA , IsraelsSJ . Platelets and platelet therapy. Journal of Pharmacological Sciences2003;93(4):381‐96. ">McNicol 2003</a>; <a href="./references#CD010983-bbs2-0104" title="ParamoJA , LecumberriR , HernandezM , RochaE . Pharmacological alternatives to blood transfusion: what is new about?. Medicina Clinica2004;122(6):231‐6. ">Paramo 2004</a>; <a href="./references#CD010983-bbs2-0105" title="PoonMC . Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?. Current Hematology Reports2003;2(2):139‐47. ">Poon 2003</a>; <a href="./references#CD010983-bbs2-0107" title="RabinowitzI . Dose of prophylactic platelet transfusions did not affect bleeding incidence or severity. ACP Journal Club2010;152(6):11. ">Rabinowitz 2010</a>; <a href="./references#CD010983-bbs2-0108" title="RaymentR , BrunskillSJ , StanworthS , SoothillPW , RobertsDJ , MurphyMF . Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database of Systematic Reviews2005, Issue 1. [DOI: 10.1002/14651858.CD004226.pub2] ">Rayment 2005</a>; <a href="./references#CD010983-bbs2-0109" title="RazzaghiA , BarkunA . Platelet transfusion threshold in patients with upper gastrointestinal bleeding: a systematic review. Journal of Clinical Gastroenterology2012;46(6):482‐6. ">Razzaghi 2012</a>; <a href="./references#CD010983-bbs2-0112" title="RobertsIAG , MurrayNA . Thrombocytopenia in the newborn. Current Opinion in Pediatrics2003;15(1):17‐23. ">Roberts 2003</a>; <a href="./references#CD010983-bbs2-0115" title="SakakuraM , WadaH . Prevention of hemorrhage occurring in patients with leukemia. Zassh (Nippon‐Naika‐Gakkai‐Zasshi)2003;92(6):1025‐9. ">Sakakura 2003</a>; <a href="./references#CD010983-bbs2-0120" title="ShehataN , TinmouthA , NaglieG , FreedmanJ , WilsonK . ABO‐identical versus non‐identical platelet transfusion: a systematic review. Transfusion2009;49:2442‐53. ">Shehata 2009</a>; <a href="./references#CD010983-bbs2-0121" title="ShenY‐MP , FrenkelEP . Acquired platelet dysfunction. Hematology/Oncology Clinics of North America2007;21(4):647‐61. ">Shen 2007</a>; <a href="./references#CD010983-bbs2-0127" title="SlichterSJ . Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfusion Medicine Reviews2004;18(3):153‐67. ">Slichter 2004</a>; <a href="./references#CD010983-bbs2-0129" title="SlichterSJ . Evidence‐based platelet transfusion guidelines. Hematology/the Education Program of the American Society of Hematology2007;2007:172‐8. ">Slichter 2007</a>; <a href="./references#CD010983-bbs2-0131" title="SlichterSJ . Effects of platelet (Plt) dose on transfusion outcomes. Transfusion Medicine2012;22:227. ">Slichter 2012</a>; <a href="./references#CD010983-bbs2-0133" title="SosaMEB . Alloimmune thrombocytopenia in the fetus: current management theories. The Journal of Perinatal &amp; Neonatal Nursing2003;17(3):181‐9. ">Sosa 2003</a>; <a href="./references#CD010983-bbs2-0137" title="StraussRG . Low‐dose prophylactic platelet transfusions: Time for further study, but too early for routine clinical practice. Transfusion2004;44(12):1680‐2. ">Strauss 2004</a>; <a href="./references#CD010983-bbs2-0138" title="StraussRG . Pretransfusion trigger platelet counts and dose for prophylactic platelet transfusions. Current Opinion in Hematology2005;12(6):499‐502. ">Strauss 2005</a>; <a href="./references#CD010983-bbs2-0141" title="TinmouthAT , FreedmanJ . Prophylactic platelet transfusions: which dose is the best dose? A review of the literature. Transfusion Medicine Reviews2003;17(3):181‐93. ">Tinmouth 2003</a>; <a href="./references#CD010983-bbs2-0153" title="WandtH . Indication for platelet transfusion in patients with haematological disease: less is more. [German]. Deutsche Medizinische Wochenschrift     2010;135(38):1877‐9. ">Wandt 2010</a>; <a href="./references#CD010983-bbs2-0156" title="WangXQ . Using evidence‐based guideline for prophylactic platelet transfusion in patient with myelodysplastic syndrome. Chinese Journal of Evidence‐Based Medicine2005;5(6):482‐4. ">Wang 2005</a>; <a href="./references#CD010983-bbs2-0159" title="WoodardP , LubinB , WaltersCMC . New approaches to hematopoietic cell transplantation for hematological diseases in children. Pediatric Clinics of North America2002;49(5):989‐1007. ">Woodard 2002</a>; <a href="./references#CD010983-bbs2-0161" title="ZellerMP , Al‐HabsiaKS , HeddleNM . Prophylactic platelet transfusions: should they be a treatment of the past?. Current Opinion in Hematology2014;21(6):521‐7. ">Zeller 2014</a>). </p> </li> <li> <p>Twenty‐six studies were not RCTs (<a href="./references#CD010983-bbs2-0004" title="AderkaD , PraffG , SantoM , WeinbergerA , PinkhasJ . Bleeding due to thrombocytopenia in acute leukaemias and reevaluation of the prophylactic platelet transfusion policy. American Journal of the Medical Sciences1986;291:147‐51. ">Aderka 1986</a>; <a href="./references#CD010983-bbs2-0021" title="CallowCR , SwindellR , RandallW , ChopraR . The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. British Journal of Haematology2002;118:677‐82. ">Callow 2002</a>; <a href="./references#CD010983-bbs2-0022" title="CameronB , RockG , OlbergB , NeurathD . Evaluation of platelet transfusion triggers in a tertiary‐care hospital. Transfusion2007;47(2):206‐11. ">Cameron 2007</a>; <a href="./references#CD010983-bbs2-0025" title="ChaouiD , ChakrounT , RobertF , RioB , BelhocineR , LegrandO , et al. Reticulated platelets: a reliable measure to reduce prophylactic platelet transfusions after intensive chemotherapy. Transfusion2005;45(5):766‐72. ">Chaoui 2005</a>; <a href="./references#CD010983-bbs2-0026" title="ChaurasiaR , ElhenceP , NityanandS , VermaA . 'Bleeding' and 'transfusion support' in acute myeloid leukemia patients: the challenges. Indian Journal of Hematology and Blood Transfusion2012;28(4):249‐50. ">Chaurasia 2012</a>; <a href="./references#CD010983-bbs2-0030" title="DecaudinD , VantelonJM , BourhisJH , FaraceF , BonnetML , GuillierM , et al. Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma. Bone Marrow Transplantation2004;34(12):1089‐93. ">Decaudin 2004</a>; <a href="./references#CD010983-bbs2-0036" title="EderAF , KennedyJM , DyBA , NotariEP , WeissJW , FangCT , et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: The American Red Cross Experience (2004‐2006). Transfusion2007;47(7):1134‐42. ">Eder 2007</a>; <a href="./references#CD010983-bbs2-0037" title="EltingLS , MartinCG , KurtinDJ , CantorSB , RubensteinEB , RodriguezS , et al. The bleeding risk index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors. Cancer2002;94(12):3252‐62. ">Elting 2002</a>; <a href="./references#CD010983-bbs2-0038" title="EltingLS , CantorSB , MartinCG , HamblinL , KurtinD , RiveraE , et al. Cost of chemotherapy‐induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer2003;97(6):1541‐50. ">Elting 2003</a>; <a href="./references#CD010983-bbs2-0041" title="FriedmannAM , SengulH , LehmannH , SchwartzC , GoodmanS . Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients?. Transfusion Medicine Reviews2002;16:34‐45. ">Friedmann 2002</a>; <a href="./references#CD010983-bbs2-0044" title="Gil‐FernandezJJ , AlegreA , Fernandez‐VillaltaMJ , PinillaI , Gomez GarciaV , MartinezC , et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non‐randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplantation1996;18:931‐5. ">Gil‐Fernandez 1996</a>; <a href="./references#CD010983-bbs2-0046" title="GmürJ , BurgerJ , SchanzU , FehrJ , SchaffnerA . Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. The Lancet1991;338:1223‐6. ">Gmür 1991</a>; <a href="./references#CD010983-bbs2-0051" title="GreenoE , McCulloughJ , WeisdorfD . Platelet utilisation and the transfusion trigger: A prospective analysis. Transfusion2007;72(2):201‐5. ">Greeno 2007</a>; <a href="./references#CD010983-bbs2-0054" title="HardanI , SoferO , ShpilbergO , Ra'ananiP , Ben‐BassatI . Safety of stringent prophylactic platelet transfusion (PT) policy for lymphoma patients treated by high dose chemotherapy (HDC) and autologous stem cell support. [20th Annual Meeting of the European Group for Bone Marrow Transplantation and 10th Meeting of the Nurses Group]. Bone Marrow Transplant1994;14(Supplement):Abstract 330. ">Hardan 1994</a>; <a href="./references#CD010983-bbs2-0077" title="LawrenceJB , YomtovianRA , HammonsT , MasarikSR , ChongkolwatanaV , CregarRJ , et al. Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leukemia &amp; Lymphoma2001;41:67‐76. ">Lawrence 2001</a>; <a href="./references#CD010983-bbs2-0093" title="NavarroJ‐T , HernandezJ‐A , RiberaJ‐M , SanchoJ‐M , OriolA , PujolM , et al. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/mL. Haematologica1998;83:998‐1000. ">Navarro 1998</a>; <a href="./references#CD010983-bbs2-0096" title="NevoS , FullerAK , BorinskyME , VogelsangGB . Acute bleeding complications in patients after haematopoietic stem cell transplantation triggers of 10 x 109 and 20 x 109 per L. Transfusion2007;47:801‐12. ">Nevo 2007</a>; <a href="./references#CD010983-bbs2-0097" title="NorolF , BierlingP , Roudot‐ThoravalF , Ferrer Le CoeurF , RieuxC , LavauxA , et al. Platelet transfusion: a dose response study. Blood1998;92:1448‐53. ">Norol 1998</a>; <a href="./references#CD010983-bbs2-0102" title="PaananenP , ArolaMO , PelliniemiTT , SalmiTT , LähteenmäkiPM . Evaluation of the effects of different transfusion trigger levels during the treatment of childhood acute lymphoblastic leukemia. Journal of Pediatric Haematology/Oncology2009;31(10):745‐9. ">Paananen 2009</a>; <a href="./references#CD010983-bbs2-0114" title="SagmeisterM , OecL , GmurJ . A restrictive platelet transfusion policy allowing long term support of outpatients with severe aplastic anaemia. Blood1999;93:3124‐6. ">Sagmeister 1999</a>; <a href="./references#CD010983-bbs2-0149" title="VermaA , PandeyP , KhetanD , ChaudharyR . Platelet transfusions in clinical practice at a multidisciplinary hospital in North India. Transfusion and Apheresis Science2008;39(1):29‐35. ">Verma 2008</a>; <a href="./references#CD010983-bbs2-0150" title="WandtH , FrankM , EhningerG , SchneiderC , BrackN , DaoudA , et al. Safety and cost effectiveness of a 10 x 109/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukaemia. Blood1998;91:3601‐6. WandtH , FrankM , LinkH , SchneiderC , BrackN , DaoudA , et al. The 10/NL trigger for prophylactic platelet transfusion in AML: a prospective comparative multicenter study. Annals of Hematology1995;70(Suppl 1):A140. ">Wandt 1998</a>; <a href="./references#CD010983-bbs2-0151" title="WandtH , FrankM , Schaefer‐EckartK , WilhelmM . Routine prophylactic platelet transfusions are not necessary in patients with acute myeloid leukaemia. A therapeutic transfusion strategy is safe. Blood2005;106(11):Abstract. WandtH , ReinelH , Schaefer‐EckartK , WilhelmM , BirkmannJ , GallmeierWM . New strategy for platelet transfusion for patients with acute myeloid leukaemia: routine prophylactic transfusion replaced by therapeutic transfusion. Blood2002;100((Abstract 2782)):706a. ">Wandt 2005</a>; <a href="./references#CD010983-bbs2-0152" title="WandtH , Schaefer‐EckartK , FrankM , BirkmannJ , WilhelmM . A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant2006;37(4):387‐92. ">Wandt 2006</a>; <a href="./references#CD010983-bbs2-0157" title="WeigandK , EnckeJ , MeyerFJ , HinkelUP , MunderM , StremmelW , et al. Low levels of prothrombin (INR) and platelets do not increase the risk of significant bleeding when placing central venous catheters. Medizinische Klinik2009;104(5):331‐5. ">Weigand 2009</a>; <a href="./references#CD010983-bbs2-0160" title="ZahurUR , AlamM . Platelet transfusion practice in a tertiary care hospital. Medical Forum Monthly2002;13(7):27‐9. ">Zahur 2002</a>). </p> </li> <li> <p>Fifty‐three records were secondary citations of excluded studies (cited as secondary references for the relevant excluded studies). </p> </li> <li> <p>One study was a non‐human study (<a href="./references#CD010983-bbs2-0148" title="Velik‐SalchnerC , HaasT , InnerhoferP , StreifW , NussbaumerW , KlinglerA , et al. The effect of fibrinogen concentrate on thrombocytopenia. Journal of Thrombosis and Haemostasis2007;5(5):1019‐25. ">Velik‐Salchner 2007</a>). </p> </li> <li> <p>One study was a study in which fewer than 80% of the participants were haematological patients, and no data were available on the haematological subgroup (<a href="./references#CD010983-bbs2-0163" title="ZumbergMS , RosarioML , PollockBH , NejameCF , AllenLS , BoyetteR , et al. A prospective randomized trial of prophylactic platelet transfusion d bleeding incidence in hematopoietic stem cell transplant (HSCT) recipients: 10,000µL vs. an 20,000 µL threshold [abstract]. 37th Annual Meeting of the American Society of Clinical Oncology, 2001 May 12‐15; San Fransisco. San Francisco: American Society of Clinical Oncology, 2001. ZumbergMS , delRoarioML , NejameCF , PollockBH , GarzarellaL , KaoKJ , et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/µL versus 20,000/µL trigger. Biology of Blood and Marrow Transplantation2002;8:569‐76. ">Zumberg 2002</a>). <a href="./references#CD010983-bbs2-0163" title="ZumbergMS , RosarioML , PollockBH , NejameCF , AllenLS , BoyetteR , et al. A prospective randomized trial of prophylactic platelet transfusion d bleeding incidence in hematopoietic stem cell transplant (HSCT) recipients: 10,000µL vs. an 20,000 µL threshold [abstract]. 37th Annual Meeting of the American Society of Clinical Oncology, 2001 May 12‐15; San Fransisco. San Francisco: American Society of Clinical Oncology, 2001. ZumbergMS , delRoarioML , NejameCF , PollockBH , GarzarellaL , KaoKJ , et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/µL versus 20,000/µL trigger. Biology of Blood and Marrow Transplantation2002;8:569‐76. ">Zumberg 2002</a> had been included in the previous review <a href="./references#CD010983-bbs2-0235" title="StanworthSJ , HydeC , HeddleN , RebullaP , BrunskillS , MurphyMF . Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD004269.pub2] ">Stanworth 2004</a>, but for this reason it has now been excluded. </p> </li> </ul> </p> </section> </section> <section id="CD010983-sec-0074"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD010983-fig-0002">Figure 2</a> and <a href="#CD010983-fig-0003">Figure 3</a> for visual representations of the 'Risk of bias' assessments across all studies and for each item in the included studies. See the <a href="./references#CD010983-sec-0150" title="">Characteristics of included studies</a> section 'Risk of bias' table for further information about the bias identified within the individual trials. </p> <div class="figure" id="CD010983-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010983-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD010983-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010983-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p>All three studies had some threats to validity (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). The majority of these potential risks were due to a lack of detail provided on the specific criteria and were thus judged as 'unclear risk' using the Cochrane grading system. </p> <section id="CD010983-sec-0075"> <h4 class="title">Allocation</h4> <p>We assessed one study as low risk of selection bias due to adequate methods of sequence generation and allocation concealment (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). We assessed the two remaining studies as unclear risk of selection bias due to the lack of information on sequence generation and allocation concealment (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>). </p> </section> <section id="CD010983-sec-0076"> <h4 class="title">Blinding</h4> <p>We assessed all three studies as high risk of performance bias due to lack of blinding of medical staff (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). </p> <p>We assessed one study as low risk of detection bias because there was adequate blinding of the bleeding assessor (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>). We assessed the other two studies as high risk of detection bias because the bleeding assessors and medical staff were unblinded (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; unpublished data of <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). </p> </section> <section id="CD010983-sec-0077"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed one study as low risk of attrition bias because the number of participants with missing outcome data were balanced across the intervention groups (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). We assessed the two remaining studies as unclear risk of selection bias due to the lack of information on the number of participants lost to follow‐up (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>). </p> </section> <section id="CD010983-sec-0078"> <h4 class="title">Selective reporting</h4> <p>We assessed all three studies as unclear risk of selection bias because as study protocols were not available, it was unclear whether any of the studies were free of selective reporting (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). </p> </section> <section id="CD010983-sec-0079"> <h4 class="title">Other potential sources of bias</h4> <section id="CD010983-sec-0080"> <h5 class="title">Protocol deviation</h5> <p>We assessed two of the three studies as at high risk of bias due to an imbalance in protocol deviations between the different arms of the studies (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). The third study was insufficiently reported for us to make an adequate assessment (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>). In <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>, there was a statistically significant difference between the two arms. Fourteen out of 37 participants with a transfusion threshold of 10 x 10<sup>9</sup>/L were affected by protocol deviations, whereas only 6 out of 41 participants with a transfusion threshold of 20 x 10<sup>9</sup>/L were affected. In <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>, the pre‐transfusion platelet count was higher than indicated in the protocol in 5.4% of platelet transfusions with a transfusion threshold of 10 x 10<sup>9</sup>/L, but only 2% of platelet transfusions with a higher transfusion trigger were transfused outside the protocol guidelines; whether this was statistically significant was not reported. </p> </section> <section id="CD010983-sec-0081"> <h5 class="title">Other potential sources</h5> <p>Two of the three studies appeared to be free of other sources of significant bias (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). The third study was insufficiently reported for us to make an adequate assessment (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>). </p> </section> </section> </section> <section id="CD010983-sec-0082"> <h3 class="title" id="CD010983-sec-0082">Effects of interventions</h3> <p>See: <a href="./full#CD010983-tbl-0001"><b>Summary of findings for the main comparison</b> Prophylactic platelet transfusion at threshold of 10,000 compared to higher transfusion threshold (20,000 or 30,000) for people with a haematological disorder</a> </p> <p>See <a href="./full#CD010983-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>In all the included studies, the study's own definition of clinically significant bleeding was used, unless otherwise stated (<a href="#CD010983-tbl-0003">Table 2</a>). The three studies used different grading systems for assessing bleeding. </p> <div class="table" id="CD010983-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Assessment and grading of bleeding</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bleeding primary outcome of study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Method of bleeding assessment reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bleeding severity scale used</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RBC usage part of bleeding severity assessment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RBC transfusion policy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. "><b>Rebulla 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New scale developed by Rebulla</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haemoglobin &lt; 80 g/L</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. "><b>Heckman 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0164" title="AjaniJA , WelshSR , RaberMN . Comprehensive criteria for assessing therapy‐induced toxicity. Cancer Investigation1990;8:141‐53. ">Ajani 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. "><b>Diedrich 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0231" title="World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset publication No. 48. Geneva: World Health Organization, 1979. ">WHO 1979</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haemoglobin &lt; 80 g/L</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>RBC = red blood cell</p> </div> </div> <section id="CD010983-sec-0083"> <h4 class="title">Number and severity of bleeding episodes</h4> <p>All three studies reported bleeding outcomes. The median study duration was less than 30 days in two studies, <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a> and <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>, and a maximum of 37 days of observation in the third study (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>) (<a href="#CD010983-tbl-0002">Table 1</a>). We therefore assumed data from all three studies was relevant to the bleeding outcomes. </p> <section id="CD010983-sec-0084"> <h5 class="title">Number of participants with at least one bleeding episode during the first 30 days of the study </h5> <p>Two of the three studies reported this (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>), and the author supplied data from the third study (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>). A meta‐analysis including 499 participants showed no difference between standard versus higher transfusion trigger levels (risk ratio (RR) 1.35, 95% confidence interval (CI) 0.95 to 1.90) (<a href="./references#CD010983-fig-0004" title="">Analysis 1.1</a>), nor was any difference seen if the studies comparing a threshold of 10 x 10<sup>9</sup>/L versus 20 x 10<sup>9</sup>/L were analysed separately (RR 1.41; 95% CI 0.95 to 2.1) (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>), to the study comparing a threshold of 10 x 10<sup>9</sup>/L versus 30 x 10<sup>9</sup>/L (RR 1.19, 95% CI 0.59 to 2.37) (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>). </p> </section> <section id="CD010983-sec-0085"> <h5 class="title">The total number of days on which bleeding occurred during the first 30 days of the study </h5> <p>This outcome could have a unit of analysis problem due to participants having more than one day of bleeding. The authors of one study performed an analysis that took into account the unit of analysis issues for this outcome (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). They found that the overall proportion of person‐days of observation during which participants experienced WHO Grade 2 bleeding or worse was 123 out of 4005 (3.1%) and 60 out of 3330 (1.8%) for the standard and higher transfusion trigger arms, respectively, giving a relative proportion of days with WHO Grade 2 or worse bleeding (RR 1.71, 95% CI 0.84 to 3.48). A permutation test for the comparison of these proportions gives a P value of 0.162, and therefore the study authors found no significant difference between study arms. The other two studies did not take into account this unit of analysis issue (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>). </p> </section> <section id="CD010983-sec-0086"> <h5 class="title">Number of participants with at least one episode of severe or life‐threatening haemorrhage during the first 30 days of the study </h5> <p>Two of the studies reported the number of participants with WHO Grade 3 and 4 bleeding (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). A meta‐analysis of this data showed no difference between a standard versus a higher trigger level (421 participants; RR 0.99, 95% CI 0.52 to 1.88) (<a href="./references#CD010983-fig-0005" title="">Analysis 1.2</a>). </p> <p>None of the studies reported the number of participants with WHO Grade 4 bleeding alone during the first 30 days of the study. </p> <p>Only <a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a> reported the number of participants with bleeding that required a red cell transfusion. The study reported no significant difference between a standard versus a higher transfusion trigger level (RR 0.66, 95% CI 0.16 to 2.68) (<a href="./references#CD010983-fig-0006" title="">Analysis 1.3</a>). </p> <p>None of the studies reported the number of participants with bleeding that caused cardiovascular compromise. </p> </section> <section id="CD010983-sec-0087"> <h5 class="title">Time to first bleeding episode from the start of study</h5> <p>One study reported the time to the first bleeding episode (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>), showing no difference between the standard and higher transfusion trigger levels (hazard ratio 1.11, 95% CI 0.64 to 1.91) (<a href="./references#CD010983-fig-0007" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD010983-sec-0088"> <h4 class="title">Mortality</h4> <section id="CD010983-sec-0089"> <h5 class="title">All‐cause mortality within 30 and 90 days</h5> <p>Two of the three studies reported all‐cause mortality (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). However, only one study reported it within a 30‐ or 90‐day study period (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>) (<a href="./references#CD010983-fig-0008" title="">Analysis 1.5</a>), and showed no difference between a standard versus a higher transfusion trigger (RR 1.78, 95% CI 0.83 to 3.81) (<a href="./references#CD010983-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD010983-sec-0090"> <h5 class="title">Mortality secondary to bleeding within 30 and 90 days</h5> <p>All three studies reported death due to bleeding, but it was only in the largest study that any deaths occurred (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). One death due to intracerebral haemorrhage in the standard trigger arm was included in the analysis (RR 2.67, 95% CI 0.11 to 64.91) (<a href="./references#CD010983-fig-0009" title="">Analysis 1.6</a>). However, two further deaths due to intracerebral haemorrhage (one in each arm of the study) occurred in participants who were randomised but not included in the analysis. If analysis of the data included all randomised participants, then there was still no evidence of a statistically significant difference in death rate between the two arms of the study (RR 1.85, 95% CI 0.17 to 20.59) (assuming that those participants for which no data forms were returned did not die secondary to bleeding) (<a href="./references#CD010983-fig-0010" title="">Analysis 1.7</a>). </p> <p><i>Mortality secondary to infection within 30 and 90 days</i> </p> <p>One of the studies reported death due to infection (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>), showing no significant difference in mortality due to infection between a standard versus a higher transfusion trigger (RR 1.57, 95% CI 0.60 to 4.14) (<a href="./references#CD010983-fig-0011" title="">Analysis 1.8</a>). </p> </section> </section> <section id="CD010983-sec-0091"> <h4 class="title">Number of platelet transfusions per participant and number of platelet components per participant within 30 days from the start of the study </h4> <p>All three studies reported on the number of platelet transfusions required per participant (<a href="#CD010983-tbl-0004">Table 3</a>). <a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a> reported the results as medians and ranges. A meta‐analysis of the other two studies, <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a> (unpublished data) and <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>, showed a reduction in the mean number of platelet transfusions required in the standard threshold arm (mean difference (MD) (fixed effect) ‐2.09, 95% CI ‐3.20 to ‐0.99) (<a href="./references#CD010983-fig-0012" title="">Analysis 1.9</a>). </p> <div class="table" id="CD010983-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of platelet transfusions and number of platelet units</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants in each arm</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of platelet transfusions/participant</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison statistics</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of platelet units transfused/participant</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison statistics</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. "><b>Diedrich 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 4; range 0 to 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 30 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 10; range 0 to 48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. "><b>Heckman 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≤ 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 8.4 ± SD 5.3*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MD ‐3.00,</p> <p>95% CI</p> <p>‐5.76 to ‐0.24*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≤ 20 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 11.4 ± SD 7.1*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. "><b>Rebulla 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 7.05 ± SD 4.56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MD ‐1.92,</p> <p>95% CI</p> <p>‐3.12 to ‐0.72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 20 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 8.97 ± SD 5.17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*unpublished data provided by the author. The paper provided medians and ranges median 7 (5 to 11) for the standard‐trigger arm and median 11 (6 to 15) for the higher‐trigger arm. </p> <p>CI = confidence interval</p> <p>MD = mean difference</p> <p>SD = standard deviation</p> </div> </div> <p>None of the studies reported on the number of platelet components per participant.</p> </section> <section id="CD010983-sec-0092"> <h4 class="title">Number of red cell transfusions per participant and number of red cell components per participant within 30 days from the start of the study </h4> <p>All three studies reported on the number of red cell transfusions required (<a href="#CD010983-tbl-0005">Table 4</a>). One of the studies reported the results as medians and ranges and showed no difference in the number of red cell transfusions required. A meta‐analysis of the other two studies, <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a> (unpublished data) and <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>, showed no difference between the two arms in the mean number of red cell transfusions required (MD (fixed effect) 0.66, 95% CI ‐0.43 to 1.76) (<a href="./references#CD010983-fig-0013" title="">Analysis 1.10</a>). </p> <div class="table" id="CD010983-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Number of red cell transfusions and number of red cell units</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants in each arm</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of red cell transfusions/participant</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison statistics</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of red cell units transfused/participant</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison statistics</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. "><b>Diedrich 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 4; range 0 to 26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 30 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 4; range 0 to 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. "><b>Heckman 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≤ 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 12.2 ± SD 6.9*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MD 1.50,</p> <p>95% CI</p> <p>‐1.22 to 4.22*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≤ 20 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 10.7 ± SD 5.1*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. "><b>Rebulla 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 9.57 ± SD 5.18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MD 0.50,</p> <p>95% CI</p> <p>‐0.70 to 1.70*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 20 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 9.07 ± SD 4.58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*unpublished data provided by the author. The paper provided medians and ranges median 11 (8 to 14) for the standard‐trigger arm and median 10 (6 to 14) for the higher‐trigger arm (P = 0.41). </p> <p>CI = confidence interval</p> <p>MD = mean difference</p> <p>SD = standard deviation</p> </div> </div> </section> <section id="CD010983-sec-0093"> <h4 class="title">Platelet transfusion interval within 30 days from the start of the study</h4> <p>None of the studies reported on the platelet transfusion interval.</p> </section> <section id="CD010983-sec-0094"> <h4 class="title">Proportion of participants requiring additional interventions to stop bleeding (surgical, medical e.g. tranexamic acid, other blood products e.g. fresh frozen plasma (FFP), cryoprecipitate) </h4> <p>None of the studies reported on additional interventions to stop bleeding.</p> </section> <section id="CD010983-sec-0095"> <h4 class="title">Overall survival within 30, 90, and 180 days from the start of the study</h4> <p>All three studies reported all‐cause survival. Only one of these studies reported overall survival within 30, 90 or 180 days, and reported actuarial survival up to 49 days after admission (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). This was not significantly different between the two groups (P = 0.31). </p> </section> <section id="CD010983-sec-0096"> <h4 class="title">Proportion of participants achieving complete remission within 30 days and 90 days from the start of the study </h4> <p>Two of the studies reported the number of participants who had achieved a complete remission (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). A meta‐analysis of this data showed no evidence of a difference between the two arms (333 participants; RR 0.92, 95% CI 0.78 to 1.09) (<a href="./references#CD010983-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD010983-sec-0097"> <h4 class="title">Total time in hospital within 30 days from the start of the study</h4> <p>All of the studies reported the length of time that participants were in hospital. As these were all reported as medians with ranges or interquartile ranges (<a href="#CD010983-tbl-0006">Table 5</a>), we could not perform a meta‐analysis. Two of the studies reported no statistically significant difference in hospital stay between the arms of the study (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>), whereas the third study did not report any P values (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). </p> <div class="table" id="CD010983-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Duration of hospital stay</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention (transfusion threshold)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants in each arm</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of days in hospital (median)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. "><b>Diedrich 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> <p>Range 9 to 89</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not significant</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 30 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> <p>Range 14 to 140</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. "><b>Heckman 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≤ 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> <p>IQR 30 to 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.25*</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≤ 20 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> <p>IQR 27 to 45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. "><b>Rebulla 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> <p>Range 3 to 64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 20 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> <p>Range 4 to 54</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*unpublished data provided by the author.</p> <p>IQR = interquartile range</p> </div> </div> </section> <section id="CD010983-sec-0098"> <h4 class="title">Adverse effects of treatments within 30 days from the start of the study</h4> <p>All of the studies reported at least one adverse event of platelet transfusions.</p> <section id="CD010983-sec-0099"> <h5 class="title">Transfusion reactions</h5> <p>Only <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a> reported on transfusion reactions secondary to platelet transfusions, and there was insufficient evidence to determine if there was a difference in the number of transfusion reactions between the two arms of the study (RR 0.07, 95% CI 0.00 to 1.09) (<a href="./references#CD010983-fig-0015" title="">Analysis 1.12</a>). </p> </section> <section id="CD010983-sec-0100"> <h5 class="title">Thromboembolic disease</h5> <p>Only <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a> reported deaths due to thromboembolic disease. There was one death in each arm of the study (<a href="./references#CD010983-fig-0016" title="">Analysis 1.13</a>). </p> </section> <section id="CD010983-sec-0101"> <h5 class="title">Transfusion‐transmitted infection</h5> <p>None of the studies reported on transfusion‐transmitted infection.</p> </section> <section id="CD010983-sec-0102"> <h5 class="title">Development of platelet antibodies</h5> <p>Only <a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a> reported on the development of human leukocyte antigen (HLA) antibodies. There was no difference shown between the two arms of the study (RR 1.10, 95% CI 0.07 to 17.31) (<a href="./references#CD010983-fig-0017" title="">Analysis 1.14</a>). </p> </section> <section id="CD010983-sec-0103"> <h5 class="title">Development of platelet refractoriness</h5> <p>Two of the studies reported on the development of platelet refractoriness (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>). A meta‐analysis involving 244 participants showed no difference between the different transfusion trigger levels (RR 0.66, 95% CI 0.16 to 2.67) (<a href="./references#CD010983-fig-0018" title="">Analysis 1.15</a>). </p> </section> </section> <section id="CD010983-sec-0104"> <h4 class="title">Quality of life (as defined by the individual studies)</h4> <p>None of the studies reported quality of life.</p> </section> <section id="CD010983-sec-0105"> <h4 class="title">Prespecified subgroup analyses</h4> <section id="CD010983-sec-0106"> <h5 class="title">Presence of fever</h5> <p>Two of the studies commented on an association between fever and bleeding risk (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). However, neither of these studies reported bleeding per treatment arm for participants with or without fever. </p> </section> <section id="CD010983-sec-0107"> <h5 class="title">Underlying disease</h5> <p>One study commented on status of underlying disease and bleeding risk (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>). </p> <section id="CD010983-sec-0108"> <h6 class="title">The number of participants with at least one clinically significant bleeding episode</h6> <p>In <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>, the authors performed a multivariate analysis that included age (&lt; 60 years versus ≥ 60 years), disease status (newly diagnosed versus relapsed leukaemia), and arm of the study, and there was no significant difference in the proportion of participants who bled between the standard and higher transfusion trigger levels. </p> </section> </section> <section id="CD010983-sec-0109"> <h5 class="title">Type of treatment</h5> <p>None of the studies reported this because in each study only one type of treatment was given (chemotherapy or allogenic stem cell transplant). </p> </section> <section id="CD010983-sec-0110"> <h5 class="title">Age of participant</h5> <p>One study commented on age of participant and bleeding risk (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>). </p> <section id="CD010983-sec-0111"> <h6 class="title">The number of participants with at least one clinically significant bleeding episode</h6> <p>In <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>, the authors performed a multivariate analysis that included age (&lt; 60 years versus ≥ 60 years), disease status (newly diagnosed versus relapsed leukaemia), and arm of the study, and there was no significant difference in the proportion of participants who bled between the standard and higher transfusion trigger levels. </p> </section> </section> <section id="CD010983-sec-0112"> <h5 class="title">Platelet component dose</h5> <p>Two of the three included studies used a platelet component dose similar to the intermediate dose used by <a href="./references#CD010983-bbs2-0130" title="AssmanS , TriulziDJ , McCulloughJ , HarrisonRW , SlichterSJ . Cost tradeoffs of low‐, medium‐, and high‐dose platelet transfusions. Transfusion2013;53(Supplement):188A. JosephsonC , SloanS , GrangerS , CastillejoM , StraussRG , SlichterS , et al. Increased incidence of Grade 2 and higher bleeding in pediatric PLADO trial patients. Transfusion2009;49(S3):19A‐20A. JosephsonCD , GrangerS , AssmannSF , CastillejoM‐I , StraussRG , SlichterSJ , et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment‐induced hypoproliferative thrombocytopenia. Blood2012;120(4):748‐60. KaufmanRM , AssmannSF , TriulziDJ , StraussRG , NessP , GrangerS , et al. Transfusion‐related adverse events in the platelet dose study. Transfusion2015;55(1):144‐53. NCT00128713 . Optimal platelet dose strategy for management of thrombocytopenia. http://clinicaltrials.gov/show/NCT00128713 (accessed 16 April 2010). SlichterSJ . Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. Journal of Clinical Apheresis2006;21:78‐84. SlichterSJ , KaufmanRM , AssmanSF , BrecherME , GernsheimerT , HillyerCD , et al. Effects of prophylactic platelet (Plt) dose on transfusion (Tx) outcomes (PLADO trial). [50th Annual Meeting of the American Society of Hematology]. Blood2008;112(11):Abstract 285. SlichterSJ , KaufmanRM , AssmannSF , McCulloughJ , TriulziDJ , StraussRG , et al. Dose of prophylactic platelet transfusions and prevention of haemorrhage. The New England Journal of Medicine2010;362:600‐13. TriulziDJ , AssmannSF , StraussRG , NessPM , HessJ , GrangerS , et al. The effect of platelet characteristics on the platelet increment and HLA alloimmunization in hypoproliferative thrombocytopenia. Transfusion2010;50(Supplement):3A. TriulziDJ , AssmannSF , StraussRG , NessPM , HessJR , KaufmanRM , et al. The impact of platelet transfusion characteristics on post‐transfusion platelet increments and clinical bleeding in patients with hypo‐proliferative thrombocytopenia. Blood2012;119(23):5553‐62. ">Slichter 2010</a> (2.2 x 10<sup>11</sup>/m<sup>2</sup> ± 25%) (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>), and one study used a dose between the intermediate and low dose used by <a href="./references#CD010983-bbs2-0130" title="AssmanS , TriulziDJ , McCulloughJ , HarrisonRW , SlichterSJ . Cost tradeoffs of low‐, medium‐, and high‐dose platelet transfusions. Transfusion2013;53(Supplement):188A. JosephsonC , SloanS , GrangerS , CastillejoM , StraussRG , SlichterS , et al. Increased incidence of Grade 2 and higher bleeding in pediatric PLADO trial patients. Transfusion2009;49(S3):19A‐20A. JosephsonCD , GrangerS , AssmannSF , CastillejoM‐I , StraussRG , SlichterSJ , et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment‐induced hypoproliferative thrombocytopenia. Blood2012;120(4):748‐60. KaufmanRM , AssmannSF , TriulziDJ , StraussRG , NessP , GrangerS , et al. Transfusion‐related adverse events in the platelet dose study. Transfusion2015;55(1):144‐53. NCT00128713 . Optimal platelet dose strategy for management of thrombocytopenia. http://clinicaltrials.gov/show/NCT00128713 (accessed 16 April 2010). SlichterSJ . Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. Journal of Clinical Apheresis2006;21:78‐84. SlichterSJ , KaufmanRM , AssmanSF , BrecherME , GernsheimerT , HillyerCD , et al. Effects of prophylactic platelet (Plt) dose on transfusion (Tx) outcomes (PLADO trial). [50th Annual Meeting of the American Society of Hematology]. Blood2008;112(11):Abstract 285. SlichterSJ , KaufmanRM , AssmannSF , McCulloughJ , TriulziDJ , StraussRG , et al. Dose of prophylactic platelet transfusions and prevention of haemorrhage. The New England Journal of Medicine2010;362:600‐13. TriulziDJ , AssmannSF , StraussRG , NessPM , HessJ , GrangerS , et al. The effect of platelet characteristics on the platelet increment and HLA alloimmunization in hypoproliferative thrombocytopenia. Transfusion2010;50(Supplement):3A. TriulziDJ , AssmannSF , StraussRG , NessPM , HessJR , KaufmanRM , et al. The impact of platelet transfusion characteristics on post‐transfusion platelet increments and clinical bleeding in patients with hypo‐proliferative thrombocytopenia. Blood2012;119(23):5553‐62. ">Slichter 2010</a> (1.1 x 10<sup>11</sup>/m<sup>2</sup> ± 25%) (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). Assuming a body surface area of 1.79 m<sup>2</sup> (<a href="./references#CD010983-bbs2-0216" title="SaccoJJ , BottenJ , MacbethF , BagustA , ClarkP . The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One2010;5(1):e8933. [DOI: 10.1371/journal.pone.0008933] ">Sacco 2010</a>), an intermediate platelet component dose equates to 3.9 x 10<sup>11</sup> ± 1.0 x 10<sup>11</sup>, and a low platelet component dose equates to 2.0 x 10<sup>11</sup> ± 0.5 x 10<sup>11</sup>. Only one analysis that included more than one study was affected by removing the data from (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>); this was the number of participants with a significant bleeding event. If only the two higher‐dose studies were included in the analysis, there was a difference between the standard and higher transfusion triggers (RR 1.71, 95% CI 1.04 to 2.82) (<a href="./references#CD010983-fig-0019" title="">Analysis 1.16</a>). However, there was no evidence of a difference between the two platelet component dose subgroups in this analysis (test for subgroup differences: Chi<sup>2</sup> = 1.73, df = 1 (P = 0.19), I<sup>2</sup> = 42.1%), and therefore only the overall result that showed no evidence of a difference should be considered. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010983-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010983-sec-0113"></div> <section id="CD010983-sec-0114"> <h3 class="title" id="CD010983-sec-0114">Summary of main results</h3> <p>This Cochrane systematic review intended to answer the question, which threshold should be used to trigger the transfusion of prophylactic platelets in participants with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation ? Only one of the four planned comparisons could be performed. No studies compared: </p> <p> <ul id="CD010983-list-0013"> <li> <p>a lower platelet count threshold (5 x 10<sup>9</sup>/L) versus a standard platelet transfusion threshold (10 x 10<sup>9</sup>/L); </p> </li> <li> <p>different platelet count thresholds (5 x 10<sup>9</sup>/L, 20 x 10<sup>9</sup>/L, 30 x 10<sup>9</sup>/L, or 50 x 10<sup>9</sup>/L) that did not include a comparison against the standard platelet transfusion threshold (10 x 10<sup>9</sup>/L); </p> </li> <li> <p>alternative thresholds to guide prophylactic platelet transfusions (e.g. platelet mass, immature platelet fraction, absolute immature platelet number). </p> </li> </ul> </p> <p>Three RCTs met our inclusion criteria for this review, all of which had data available and compared a standard platelet transfusion threshold (10 x 10<sup>9</sup>/L) versus a higher platelet count threshold (20 x 10<sup>9</sup>/L, 30 x 10<sup>9</sup>/L, or 50 x 10<sup>9</sup>/L). </p> <p>These trials were carried out from 1991 to 2001 and enrolled 520 participants from fairly comparable patient populations. </p> <p>The findings of the review led to the following main conclusions:</p> <p>Overall, a standard transfusion trigger of 10 x 10<sup>9</sup>/L appears to be as effective as a higher transfusion trigger of 20 x 10<sup>9</sup>/L or 30 x 10<sup>9</sup>/L at preventing clinically significant bleeding. This included no evidence of a difference in the: </p> <p> <ul id="CD010983-list-0014"> <li> <p>number of participants with a clinically significant bleeding event (WHO Grade 2 or above); </p> </li> <li> <p>number of days with clinically significant bleeding (adjusted for repeated events);</p> </li> <li> <p>number of participants with severe or life‐threatening bleeding;</p> </li> <li> <p>time to first clinically significant bleeding episode.</p> </li> </ul> </p> <p>This effect was seen irrespective of the participant's age or underlying disease stage. However, all of this evidence was of low quality, due to risk of bias within the included studies and imprecision of the estimate due to the small total numbers of participants, events, or both. </p> <p> <ul id="CD010983-list-0015"> <li> <p>There was a reduction observed in the number of platelet transfusions required using a threshold of 10 x 10<sup>9</sup>/L. </p> </li> <li> <p>There was no evidence of a difference in all‐cause mortality.</p> </li> <li> <p>None of the studies reported quality of life.</p> </li> </ul> </p> <p>There were no differences between the groups with regards to mortality due to bleeding or infection, red cell transfusion requirements, survival, remission rates, hospital stay, or adverse events. </p> </section> <section id="CD010983-sec-0115"> <h3 class="title" id="CD010983-sec-0115">Overall completeness and applicability of evidence</h3> <p>This review provides the most up‐to‐date assessment of the effectiveness and safety of a a standard platelet transfusion threshold (10 x 10<sup>9</sup>/L) versus a higher platelet count threshold (20 x 10<sup>9</sup>/L, 30 x 10<sup>9</sup>/L, or 50 x 10<sup>9</sup>/L) to guide administration of prophylactic platelet transfusions. </p> <p>The effectiveness and safety of the three other planned comparisons could not be evaluated because no study assessed these comparisons. These planned comparisons were: </p> <p> <ul id="CD010983-list-0016"> <li> <p>a lower platelet count threshold (5 x 10<sup>9</sup>/L) versus standard platelet transfusion threshold (10 x 10<sup>9</sup>/L); </p> </li> <li> <p>different platelet count thresholds (5 x 10<sup>9</sup>/L, 20 x 10<sup>9</sup>/L, 30 x 10<sup>9</sup>/L, or 50 x 10<sup>9</sup>/L) that did not include a comparison against the standard platelet transfusion threshold (10 x 10<sup>9</sup>/L); </p> </li> <li> <p>alternative thresholds to guide prophylactic platelet transfusions (e.g. platelet mass, immature platelet fraction, absolute immature platelet number). </p> </li> </ul> </p> <p>(See <a href="#CD010983-sec-0020">How the intervention might work</a> for further information on why these planned comparisons were clinically relevant.) </p> <p>This updated review identified no new studies and no ongoing studies. It is unclear why no future studies are planned; it may be because of the large number of participants required within a study to demonstrate a statistically significant difference (<a href="./references#CD010983-bbs2-0232" title="ZiskJL , MackleyA , ClearlyG , ChangE , ChristensenRD , PaulDA . Transfusing neonates based on platelet count vs. platelet mass: a randomized feasibility‐pilot study. Platelets2014;25(7):513‐6. ">Zisk 2014</a>). </p> <p>There was no evidence that people with haematological disorders receiving myelosuppressive chemotherapy or HSCT had an increase in clinically significant bleeding events with a standard platelet count threshold compared to a higher platelet count threshold. </p> <p>The results of this meta‐analysis should not be interpreted without considering the impact of the following factors: </p> <p> <ul id="CD010983-list-0017"> <li> <p>The recording of bleeding is subjective, and all three included studies used different grading systems to measure the severity of bleeding (<a href="#CD010983-tbl-0003">Table 2</a>). </p> </li> <li> <p>No difference was demonstrated in the number of participants with clinically significant bleeding, but the 95% confidence interval (0.95 to 1.9) demonstrates that a clinically important difference in the proportion of participants with bleeding could have been missed. When combined, the studies were not adequately powered to detect a difference. In <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>, which included 255 participants, the power calculations were based on the assumption that the rate of WHO Grade 2 or above bleeding was 30%, but the actual rate in this study was 20%. If we assume the rate of bleeding was similar in all three studies, to detect a 50% increase in the rate of bleeding (i.e. from 20% to 30%) with 80% power would require 293 participants per arm of the study (586 in total), and to detect a 25% increase in the rate of bleeding (i.e. from 20% to 25%) with 80% power would require 1098 participants per arm of the study (2196 in total). As there were only 499 participants within all three studies, the meta‐analysis would not be sufficiently powered to detect a 50% increase in the rate of bleeding in the restrictive transfusion arm. </p> </li> <li> <p>There were important differences between the studies that might affect the degree of confidence that can be placed on the assertion of equivalence between higher (20 or 30 x 10<sup>9</sup>/L) and standard (10 x 10<sup>9</sup>/L) platelet count thresholds for prophylactic platelet transfusions. The treatment protocols for administration of platelets varied, particularly the circumstances for which platelet transfusions could be given. In <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>, platelets could be given to participants in the 10 x 10<sup>9</sup>/L threshold arm if the platelet count was in the range of 10 to 20 x 10<sup>9</sup>/L and the participant's temperature was above 38°C. This meant that 22.6% of platelet transfusions were given above the threshold of 10 x 10<sup>9</sup>/L. In <a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a> and <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>, there were no changes in the transfusion threshold in the presence of fever. </p> </li> <li> <p>Not all endpoints from all the studies could be incorporated into a meta‐analysis due to differences in the ways the studies had reported the outcomes. </p> </li> <li> <p>Some of the planned outcomes were not reported by any of the studies.</p> </li> <li> <p>In all studies, the number of participants that were lost to follow‐up was quite low, and therefore there were minimal implications of missing data outcomes. </p> </li> </ul> </p> </section> <section id="CD010983-sec-0116"> <h3 class="title" id="CD010983-sec-0116">Quality of the evidence</h3> <p>All studies were RCTs, however they were all prone to bias and had threats to validity. The ability to assess the risk of bias was limited by most of the studies not reporting study methodology in adequate detail. For example, only one of the three studies reported allocation concealment as adequate (<a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>), and in all three studies blinding of participants was unknown. </p> <p>None of the studies blinded medical staff caring for the participants to their patient's study allocation, and two of the three studies did not blind outcome assessors to the participants' study allocations (<a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>). This is likely to reflect the inherent difficulties with blinding platelet transfusion trials because medical staff caring for participants cannot be blinded to their patients' blood results. </p> <p>We assessed the GRADE quality of evidence as low for:</p> <p> <ul id="CD010983-list-0018"> <li> <p>number of participants with at least one clinically significant bleeding event up to 30 days from study entry; </p> </li> <li> <p>number of participants with WHO Grade 3 or 4 bleeding up to 30 days from study entry;</p> </li> <li> <p>time to first clinically significant bleeding event;</p> </li> <li> <p>mortality from all causes up to 30 days from study entry;</p> </li> <li> <p>number of platelet transfusions per participant.</p> </li> </ul> </p> <p>The quality of the evidence was low due to risk of bias within the included studies and imprecision of the estimate due to the small total numbers of participants, events, or both. </p> <p>We did not perform a GRADE assessment of quality of the evidence for quality of life because no study reported this outcome, or for number of days with bleeding, as we relied on the study authors' own analysis. </p> </section> <section id="CD010983-sec-0117"> <h3 class="title" id="CD010983-sec-0117">Potential biases in the review process</h3> <p>There were no obvious biases within the review process. We conducted a wide search, which included ongoing trial databases and contact with researchers in the field; we carefully assessed the relevance of each paper identified; and we made no restrictions for the language in which the paper was originally published or its publication status. We performed all screening and data extractions in duplicate. We prespecified all outcomes and subgroups prior to analysis. The numbers of included studies were insufficient for us to combine to complete a funnel plot in order to examine the risk of publication bias. </p> </section> <section id="CD010983-sec-0118"> <h3 class="title" id="CD010983-sec-0118">Agreements and disagreements with other studies or reviews</h3> <p>One platelet transfusion review was recently published in this area (<a href="./references#CD010983-bbs2-0202" title="KumarA , MhaskarR , GrossmanBJ , KaufmanRM , TobianAAR , KleinmanS , et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion2015;55(5):1116‐27. ">Kumar 2014</a>). <a href="./references#CD010983-bbs2-0202" title="KumarA , MhaskarR , GrossmanBJ , KaufmanRM , TobianAAR , KleinmanS , et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion2015;55(5):1116‐27. ">Kumar 2014</a> performed a systematic review of the use of platelet transfusions in common clinical settings, including the comparison of prophylactic versus therapeutic platelet transfusions. Their review identified the same three studies included in this review (<a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. ">Diedrich 2005</a>; <a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. ">Heckman 1997</a>; <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a>), as well as including the data from <a href="./references#CD010983-bbs2-0163" title="ZumbergMS , RosarioML , PollockBH , NejameCF , AllenLS , BoyetteR , et al. A prospective randomized trial of prophylactic platelet transfusion d bleeding incidence in hematopoietic stem cell transplant (HSCT) recipients: 10,000µL vs. an 20,000 µL threshold [abstract]. 37th Annual Meeting of the American Society of Clinical Oncology, 2001 May 12‐15; San Fransisco. San Francisco: American Society of Clinical Oncology, 2001. ZumbergMS , delRoarioML , NejameCF , PollockBH , GarzarellaL , KaoKJ , et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/µL versus 20,000/µL trigger. Biology of Blood and Marrow Transplantation2002;8:569‐76. ">Zumberg 2002</a>. We excluded the data from <a href="./references#CD010983-bbs2-0163" title="ZumbergMS , RosarioML , PollockBH , NejameCF , AllenLS , BoyetteR , et al. A prospective randomized trial of prophylactic platelet transfusion d bleeding incidence in hematopoietic stem cell transplant (HSCT) recipients: 10,000µL vs. an 20,000 µL threshold [abstract]. 37th Annual Meeting of the American Society of Clinical Oncology, 2001 May 12‐15; San Fransisco. San Francisco: American Society of Clinical Oncology, 2001. ZumbergMS , delRoarioML , NejameCF , PollockBH , GarzarellaL , KaoKJ , et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/µL versus 20,000/µL trigger. Biology of Blood and Marrow Transplantation2002;8:569‐76. ">Zumberg 2002</a> from this review because fewer than 80% of participants had a haematological malignancy, and no subgroup data were available. The <a href="./references#CD010983-bbs2-0163" title="ZumbergMS , RosarioML , PollockBH , NejameCF , AllenLS , BoyetteR , et al. A prospective randomized trial of prophylactic platelet transfusion d bleeding incidence in hematopoietic stem cell transplant (HSCT) recipients: 10,000µL vs. an 20,000 µL threshold [abstract]. 37th Annual Meeting of the American Society of Clinical Oncology, 2001 May 12‐15; San Fransisco. San Francisco: American Society of Clinical Oncology, 2001. ZumbergMS , delRoarioML , NejameCF , PollockBH , GarzarellaL , KaoKJ , et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/µL versus 20,000/µL trigger. Biology of Blood and Marrow Transplantation2002;8:569‐76. ">Zumberg 2002</a> study was at high risk of bias due to the significant number of platelet transfusions (31.9%) given above the level of 10 x 10<sup>9</sup>/L. </p> <p>The <a href="./references#CD010983-bbs2-0202" title="KumarA , MhaskarR , GrossmanBJ , KaufmanRM , TobianAAR , KleinmanS , et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion2015;55(5):1116‐27. ">Kumar 2014</a> review only included the outcome measures of all‐cause mortality, mortality due to bleeding, bleeding ("major" or "significant" bleeding as defined in each study), and number of platelet transfusions. They found no difference in significant bleeding between a standard and higher threshold and a significant decrease in the number of platelet transfusions. This was similar to the finding of our review. </p> <p>The <a href="./references#CD010983-bbs2-0202" title="KumarA , MhaskarR , GrossmanBJ , KaufmanRM , TobianAAR , KleinmanS , et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion2015;55(5):1116‐27. ">Kumar 2014</a> review did not perform a detailed assessment of the risk of bias of the included studies, nor did it consider reasons for heterogeneity between the included studies. Our review is more comprehensive and includes data on different bleeding outcome measures, adverse effects of transfusion, and unpublished study data provided by the authors. We have performed a detailed quality assessment of all identified studies and highlighted their weaknesses and shortcomings. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010983-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010983-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010983-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010983-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 1 Numbers of participants with a significant bleeding event." data-id="CD010983-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 1 Numbers of participants with a significant bleeding event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 2 Number of participants with WHO Grade 3 or 4 bleeding." data-id="CD010983-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 2 Number of participants with WHO Grade 3 or 4 bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 3 Number of participants with bleeding requiring a red cell transfusion." data-id="CD010983-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 3 Number of participants with bleeding requiring a red cell transfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 4 Time to first bleeding episode." data-id="CD010983-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 4 Time to first bleeding episode. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 5 All‐cause mortality." data-id="CD010983-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 5 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 6 Mortality due to bleeding." data-id="CD010983-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 6 Mortality due to bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 7 Mortality due to bleeding (all randomised participants)." data-id="CD010983-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 7 Mortality due to bleeding (all randomised participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 8 Mortality due to infection." data-id="CD010983-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 8 Mortality due to infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 9 Mean number of platelet transfusions per participant." data-id="CD010983-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 9 Mean number of platelet transfusions per participant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 10 Mean number of red cell transfusions per participant." data-id="CD010983-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 10 Mean number of red cell transfusions per participant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 11 Complete remission rates." data-id="CD010983-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 11 Complete remission rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 12 Numbers of participants with platelet transfusion reactions." data-id="CD010983-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 12 Numbers of participants with platelet transfusion reactions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 13 Number of participants with thromboembolic disease." data-id="CD010983-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 13 Number of participants with thromboembolic disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 14 Number of participants requiring HLA‐matched platelets." data-id="CD010983-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 14 Number of participants requiring HLA‐matched platelets. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 15 Number of participants with platelet refractoriness." data-id="CD010983-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 15 Number of participants with platelet refractoriness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010983-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/urn:x-wiley:14651858:media:CD010983:CD010983-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_t/tCD010983-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 16 Numbers of participants with a significant bleeding event." data-id="CD010983-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level, Outcome 16 Numbers of participants with a significant bleeding event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/media/CDSR/CD010983/image_n/nCD010983-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010983-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Prophylactic platelet transfusion at threshold of 10,000 compared to higher transfusion threshold (20,000 or 30,000) for people with a haematological disorder</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylactic platelet transfusion at threshold of 10,000 compared to higher transfusion threshold (20,000 or 30,000) for prevention of haemorrhage after chemotherapy and stem cell transplantation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with a haematological disorder<br/> <b>Settings:</b> Receiving intensive chemotherapy or a stem cell transplant<br/> <b>Intervention:</b> Prophylactic platelet transfusion at threshold of 10 x 10<sup>9</sup>/L<br/> <b>Comparison:</b> Higher transfusion threshold (20 x 10<sup>9</sup>/L or 30 x 10<sup>9</sup>/L) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Higher transfusion threshold </b> </p> <p><b> (20 x 10<sup>9</sup>/L or 30 x 10<sup>9</sup>/L)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Prophylactic platelet transfusion at threshold of 10 x 10<sup>9</sup>/L</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Numbers of participants with at least 1 clinically significant bleeding event up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> <br/> (168 to 336) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.35</b> <br/> (0.95 to 1.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The definition of clinically significant bleeding varied between studies, because there were differences in the way bleeding was graded </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of days on which clinically significant bleeding occurred per participant up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>3</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with WHO Grade 3 or 4 bleeding up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>82 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b> </p> <p>(43 to 154)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> </p> <p>(0.52 to 1.88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>421</p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first bleeding episode (days)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.11</b> </p> <p>(0.64 to 1.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of platelet transfusions per participant up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean number of platelet transfusions per participant in the 10 x 10<sup>9</sup>/L group was<br/> <b>2.09 lower</b> <br/> (3.2 to 0.99 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality from all causes up to 30 days from study entry</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>134 per 1000</b> </p> <p>(62 to 286)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.78</b> </p> <p>(0.83 to 3.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies reported quality of life</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>HR:</b> Hazard ratio; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The number of participants from all three studies may not be large enough to detect a clinically significant difference. The confidence intervals are wide, and therefore there is uncertainty about the result. The level of evidence was downgraded by 1 due to imprecision. </p> <p><sup>2</sup>All of the studies were at high risk of bias due to lack of blinding and more protocol deviations in the standard‐trigger arm (10 x 10<sup>9</sup>/L). The Rebulla study did not perform an intention‐to‐treat analysis and excluded 2 participants who died within 24 hours of entering the study. The level of evidence was downgraded by 1 due to risk of bias. </p> <p><sup>3</sup>The authors of <a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. ">Rebulla 1997</a> reported a relative proportion of days with WHO Grade 2 or worse bleeding of 1.71 (95% CI 0.84 to 3.48) for the standard versus higher transfusion trigger arms. A permutation test for the comparison of these proportions gives a P value of 0.162, and therefore no significant difference between study arms was found. These results are the authors' own results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Prophylactic platelet transfusion at threshold of 10,000 compared to higher transfusion threshold (20,000 or 30,000) for people with a haematological disorder</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010983-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of the included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Platelet component dose</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of platelet component</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcome</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. "><b>Diedrich 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages undergoing<br/> an allogeneic HSCT </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic plt transfusion if plt count &lt; 10 x 10<sup>9</sup>/L<br/> versus<br/> prophylactic plt transfusion if plt count &lt; 30 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average yield (mean ± SD)</p> <p>4.10 x 10<sup>11</sup> ± 0.2 x 10<sup>11</sup> (buffy coat) </p> <p>3.80 x 10<sup>11</sup> ± 0.2 x 10<sup>11</sup> (apheresis) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum duration of observation was 37 days (7 days pre‐HSCT and 30 days post‐HSCT). No information available on the number of participants who died or were lost to follow‐up </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leucodepleted, ABO ‐matched, irradiated<br/> pooled random‐donor platelets (buffy coat) 85%<br/> Apheresis 15% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of platelet transfusions</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. "><b>Heckman 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults with acute leukaemia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic plt transfusion if plt count ≤ 10 x 10<sup>9</sup>/L </p> <p>versus</p> <p>prophylactic plt transfusion if plt count ≤ 20 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 apheresis unit.</p> <p>Average yield each study year (number of transfusions)</p> <p>4.9 x 10<sup>11</sup> 1991 (n = 502) </p> <p>4.5 x10<sup>11</sup> 1992 (n = 418) </p> <p>4.7 x 10<sup>11</sup> 1993 (n = 399) </p> <p>4.0 x 10<sup>11</sup> 1994 (n = 400) </p> <p>4.3 x 10<sup>11</sup> 1995 (n = 398) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 24 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leucodepleted</p> <p>Apheresis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. "><b>Rebulla 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adolescents and adults with AML</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prophylactic plt transfusion if plt count &lt; 10 x 10<sup>9</sup>/L </p> <p>versus</p> <p>prophylactic plt transfusion if plt count &lt; 20 x 10<sup>9</sup>/L </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median</p> <p>2.2 x 10<sup>11</sup> (pooled) </p> <p>2.8 x 10<sup>11</sup> (apheresis) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 27.8 to 29.7 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apheresis and pooled products</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency and severity of haemorrhage</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>AML = acute myeloid leukaemia</p> <p>HSCT = haematopoietic stem cell transplant</p> <p>plt = platelet</p> <p>SD = standard deviation</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of the included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010983-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Assessment and grading of bleeding</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bleeding primary outcome of study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Method of bleeding assessment reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bleeding severity scale used</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RBC usage part of bleeding severity assessment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RBC transfusion policy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. "><b>Rebulla 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New scale developed by Rebulla</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haemoglobin &lt; 80 g/L</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. "><b>Heckman 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0164" title="AjaniJA , WelshSR , RaberMN . Comprehensive criteria for assessing therapy‐induced toxicity. Cancer Investigation1990;8:141‐53. ">Ajani 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. "><b>Diedrich 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010983-bbs2-0231" title="World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset publication No. 48. Geneva: World Health Organization, 1979. ">WHO 1979</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haemoglobin &lt; 80 g/L</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>RBC = red blood cell</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Assessment and grading of bleeding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010983-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of platelet transfusions and number of platelet units</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants in each arm</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of platelet transfusions/participant</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison statistics</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of platelet units transfused/participant</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison statistics</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. "><b>Diedrich 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 4; range 0 to 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>&lt; 0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 30 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 10; range 0 to 48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. "><b>Heckman 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≤ 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 8.4 ± SD 5.3*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MD ‐3.00,</p> <p>95% CI</p> <p>‐5.76 to ‐0.24*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≤ 20 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 11.4 ± SD 7.1*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. "><b>Rebulla 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 7.05 ± SD 4.56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MD ‐1.92,</p> <p>95% CI</p> <p>‐3.12 to ‐0.72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 20 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 8.97 ± SD 5.17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>*unpublished data provided by the author. The paper provided medians and ranges median 7 (5 to 11) for the standard‐trigger arm and median 11 (6 to 15) for the higher‐trigger arm. </p> <p>CI = confidence interval</p> <p>MD = mean difference</p> <p>SD = standard deviation</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of platelet transfusions and number of platelet units</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010983-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Number of red cell transfusions and number of red cell units</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants in each arm</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of red cell transfusions/participant</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison statistics</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of red cell units transfused/participant</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison statistics</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Short‐term follow‐up (up to 30 days)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. "><b>Diedrich 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 4; range 0 to 26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 30 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 4; range 0 to 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. "><b>Heckman 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≤ 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 12.2 ± SD 6.9*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MD 1.50,</p> <p>95% CI</p> <p>‐1.22 to 4.22*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≤ 20 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 10.7 ± SD 5.1*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. "><b>Rebulla 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 9.57 ± SD 5.18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MD 0.50,</p> <p>95% CI</p> <p>‐0.70 to 1.70*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 20 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 9.07 ± SD 4.58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>*unpublished data provided by the author. The paper provided medians and ranges median 11 (8 to 14) for the standard‐trigger arm and median 10 (6 to 14) for the higher‐trigger arm (P = 0.41). </p> <p>CI = confidence interval</p> <p>MD = mean difference</p> <p>SD = standard deviation</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Number of red cell transfusions and number of red cell units</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010983-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Duration of hospital stay</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention (transfusion threshold)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants in each arm</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of days in hospital (median)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0001" title="DiedrichB , RembergerM , ShanwellA , SvahnBM , RingdenO . A prospective randomised trial of a prophylactic platelet transfusion trigger of 10 x 109 per L versus 30 x 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion2005;45:1064‐72. "><b>Diedrich 2005</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> <p>Range 9 to 89</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not significant</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 30 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> <p>Range 14 to 140</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0002" title="HeckmanK , WeinerGJ , StraussRG , JonesMP , BurnsCP . Randomized evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukaemia (American Society of Hematology 35th Annual Meeting). Blood1993;82(Abstract):192a. HeckmanKD , WeinerGJ , DavisCS , StraussRG , JonesMP , BurnsCP . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukaemia: 10 x 109/L versus 20 x 109/L. Journal of Clinical Oncology1997;15:1143‐9. "><b>Heckman 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≤ 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> <p>IQR 30 to 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.25*</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>≤ 20 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> <p>IQR 27 to 45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010983-bbs2-0003" title="CookRJ , HeddleNM , RebullaP , SigouinCS , WebertKE . Methods for the analysis of bleeding outcomes in randomised trials of platelet transfusion triggers. Transfusion2004;44:1135‐42. Finazzi G for the GIMEMA Group. The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukaemia (AML). Thrombosis and Haemostasis1997;78(Supplement):768‐9. GIMEMA Group. Interim report from the platelet transfusion trigger trial (PTTT): a prospective controlled study on bleeding risk in acute myeloid leukaemia (AML) patients randomized to be transfused at ≤10 versus ≤20 x 109/L platelets. Blood1996;88(10):443a. HeddleNM , CookRJ , SigouinC , SlichterSJ , MurphyM , RebullaP . A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukaemia. Transfusion2006;46:903‐11. RebullaP , FinazziG , MarangoniF , AvvisatiG , GugliottaL , TognoniG , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. The New England Journal of Medicine1997;337:1870‐5. WebertKE , CookRJ , SigouinCS , RebullaP , HeddleNM . The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica2006;91(11):1530‐7. "><b>Rebulla 1997</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 10 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> <p>Range 3 to 64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 20 x 10<sup>9</sup>/L</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> <p>Range 4 to 54</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*unpublished data provided by the author.</p> <p>IQR = interquartile range</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Duration of hospital stay</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/full#CD010983-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010983-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Numbers of participants with a significant bleeding event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.95, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Platelet threshold &lt; 10 vs. &lt; 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.95, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Platelet threshold &lt; 10 vs. &lt; 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.59, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants with WHO Grade 3 or 4 bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.52, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Platelet threshold &lt; 10 vs. &lt; 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.58, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Platelet threshold &lt; 10 vs. &lt; 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.14, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of participants with bleeding requiring a red cell transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Time to first bleeding episode <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mortality due to bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mortality due to bleeding (all randomised participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mortality due to infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mean number of platelet transfusions per participant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.09 [‐3.20, ‐0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mean number of red cell transfusions per participant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [‐0.43, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Complete remission rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.78, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Numbers of participants with platelet transfusion reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Number of participants with thromboembolic disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Number of participants requiring HLA‐matched platelets <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Number of participants with platelet refractoriness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.16, 2.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Numbers of participants with a significant bleeding event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.95, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Platelet component dose (2.9 x 1011 to 4.9 x 1011)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.04, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Platelet component dose (&lt; 2.9 x 1011)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.66, 1.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010983.pub2/references#CD010983-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010983.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010983-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010983-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010983-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010983\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010983\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010983\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010983\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010983\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010983.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010983.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010983.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010983.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010983.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725639495"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010983.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725639498"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010983.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e80265ca6f466',t:'MTc0MDcyNTYzOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 